AUTHOR INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E and a number.
Page references to Supplement 1 (February 2002) and Supplement 2 (May 2002) are preceded, respectively, by S1: and S2:.

Abbott, K. C., 1011
Abe, S., 392
Abreo, K., 824
Abu-Alfa, A. K., 102
Adcox, M. J., 549
Adler, S., 76
Agarwal, R., 486, 1190
Agodoa, L. Y., 445, 513, 889, 1011
Aibara, K., 937
Ajami, A., 195
Akagi, T., 3:E12
Akagi, Y., 948
Akai, Y., 695
Akdeniz, A., 1183
Akhtar, J., 834
Alam, M. G., 556
Alappan, R., 1102
Alaupovic, P., 67
Alpers, C. E., 876
Amato, A., 76
Ambrosch, A., 972
Amoedo, M. L., 60
Anai, H., 937
Anania, M. C., 1176
Andany, M. A., 762
Andreucci, M., 266
Arbab-Zadeh, A., 813
Arimura, Y., 1:E4
Arnaout, M. A., 587
Aronoff, G., 426
Assadi, F. K., 6:E24
Astor, B. C., 920
Athienites, N. V., 324
Attman, P.-O., 67
Aviles, X., 1018

Bach, D., 28
Bahner, U., 862
Bailie, G., 426
Bailie, G. R., 1270
Bakris, G. L., 899
Ballantine, R., 3:E13
Balletta, M. M., 266
Banerjee, D., 2:E9
Bankson, D. D., 134
Bartlett, S. T., 1096
Bartoli, B., 1176
Bas, J., 5:E21
Bass, E. B., 116
Batuman, V., 460
Baumgarten, D. A., 663
Beaubien, E. R., 834
Beck, G., 513
Becker, B. N., 1088
Becker, Y. T., 1088
Belasco, A. G., 805
Belz, M. M., 1127
Berg, B. W., 1:E3
Bernardi, M., 713
Béroud, C., 2:E6
Bertani, T., 713
Bertram, J. F., 679
Bhargava, V., 813
Bia, F. J., 1278
Bichet, D. G., 737
Biem, H. J., 834
Bisesti, V., 266
Bissler, J. J., 966
Blahut, S. A., 753, 1096
Blantz, R. C., 159
Blaschke, S., 2:E11
Bloom, R., 3:E16
Bobelu, A., 358
Boeschoten, E. W., 108
Böhler, J., 28
Boldorini, R., 713
Boletis, I. N., 469
Bommer, J., 2:E10
Borgmann, S., 972
Borriello, A., 958
Bossuyt, P. M. M., 108
Botey, A., 60
Bottini, P. V., 1:E2
Brass, E. P., 76
Braun, N., 28
Brown, E. A., 1318
Brozena, S., 3:E16
Brunkhorst, R., 862
Brunori, G., 850
Budisavljevic, M. N., 769
Buffington, D. A., 1078
Burckle, C., 2:E6
Burke, G. W., 2:E9
Burnier, M., 1135
Burrowes, J. D., 245
Buyan, N., 1323
Byrd-Holt, D., 445
Byrne, M. C., 769

Camerini, C., 850
Campbell, A., 721
Campistol, J. M., 1025
Cancarini, G. C., 850
Capuano, A., 266
Caputo, C., 6:E23
Carangio, C., 958
Cardellach, F., 1025
Carlson, L., 257
Carpenito, G., 4:E1
Carrera, M., 5:E21
Carreras, L., 5:E21
Casademont, J., 1025
Castilla, J. J., 2:E7
Castillo, L., 195
Cattoretti, G., 892
Cefalu, W. T., 297
Chae, D.-W., 55
Chan, J. C.-N., 1054
Chan, M., 369
Chandran, P. K. G., 587
Chang, J. W., 1213
Chang, S.-C., 2:E8
Chase, C., 843
Chatoth, D. K., 556
Chauveau, D., 2:E6
Chavers, B., 445
Chen, A., 3:E14
Chen, C.-H., 539
Chen, H.-C., 1245
Chen, J., 460
Chen, S., 1
Chen, S.-C., 784
Chen, W.-C., 2:E8
Cheng, C.-H., 539
Cheong, H. I., 1001
Chertow, G. M., 203
Cheung, C., 1153
Chiba, S., 493
Chien, L.-C., 1245
Choi, P. C. L., 401
Choi, Y., 1001
Chow, K. M., 401, 1054
Chow, K.-M., 1287
Christenson, R. H., 1096
Chu, P., 3:E14
Chuahirun, T., 376
Chuang, H.-Y., 1245
Cimanga, R. K., 3:E13
Cisneros, J. M., 2:E7
Claessen, N., 407
Claeys, M., 3:E13
Clow, P. W., 1018
Cluzel, P., 730
Coburn, S. P., 134
Cockram, D. B., 245
Collins, A. J., 784
Comper, W. D., 899
Connolly, M. K., 203
Constantini, E., 784

Conti, A., 266
Cook, H. T., 1162
Coresh, J., 324, 445, 920
Correas, J.-M., 2:E6
Courgi, R. G., 6:E23
Craver, L., 60
Cress, C. L., 828
Cruess, D., 1011
Cui, Y., 876
Cuiffo, B. P., 183
Cuyckens, F., 3:E13

D'Agati, V. D., 892, 1118
Dalton, D., 358
Dammers, R., 1206
Danesh, F. R., 3:E19
Danielson, B., 762
Davaris, P. S., 469
Davidson, R. L., 549
Davies, M., 985
Deabreu, D., 1231
Deane, J., 1270
De Broe, M. E., 3:E13
Deira, J., 594
Dekker, F. W., 108
Delling, G., 580
DeMaria, A. N., 813
Deray, G., 730
Derfler, K., 415
Derici, Ü., 1323
Desai, A., 2:E9
DeTorres, J. P., 1307
Devarajan, P., 625
Devuyst, O., 737
Dierkes, J., 972
Di Paolo, S., 776
Di Tola, M., 1176
Dixon, B. S., 92
Dohi, K., 695
Domenig, C., 580
Domrongkitchaiporn, S., 383
Donnelly, L. F., 966
Donovan, V., 6:E23
Dougan, T., 1162
Drewe, J., 3:E18
Duclos, J.-M., 2:E6
Dunn, S. R., 486
Dworkin, L. D., 1328
Dwyer, J. T., 245

Ebben, J., 784
Eberhardt, M. S., 445
Eggers, P. W., 796
Eknoyan, G., 889
Emmett, M., 1123
Engelgau, M., 445
Engelman, C., 689
Epstein, D., 6:E23
Era, S., 1040
Erin, C. A., 611
Escudero, E., 1135
Esler, A., 76
Evans, D., 1162
Evans, R. A., 985
Evenepoel, P., 315

Faiyaz, R., 824
Faller, B., 862
Fan, P.-Y., 1310
Fan, Z., 769
Fangman, J., 92
Farquhar, F., 872
Farr, A. G., 876
Faulkner, M., 513
Feng, S., 533
Ferguson, C., 308
Fernández, E., 60
Fernvik, E., 854
Fick-Brosnahan, G. M., 1127
Filho, J. C. D., 862
Fine, P. L., 1118
Fink, J. C., 753, 1096
Fink, N. E., 116, 324
Finkelstein, E. S., 1278
Finkelstein, F. O., 1278
Fishbane, S., 6:E23
Fissell, W. H., 1078
Floege, J., 985
Florquin, S., 407
Fofi, C., 1176
Fogo, A. B., liii, 433
Foley, R. N., 1153
Fortunato, M., 713
Francis, M. E., 445
Francois, D. J., 892
Frankenfield, D. L., 796
Freytag, C., 972
Frieda, P., 862
Fujimi, S., 503
Fujimura, A., 127
Fukagawa, M., 525
Fukasawa, I., 392
Fukuda, K., 1:E4
Fukui, M., 1255
Fukushima, C., 127
Funabiki, K., 1255
Funamizu, M., 1032
Fünfstück, R., 28
Furuta, T., 493

Gabbai, F. B., 159
Gallagher, H., 42
García, C., 60
García, L., 60
García Falcón, T., 337
Garlipp, C. R., 1:E2
Garrido, J., 594
Gassman, J., 146
Geddes, C. C., 308
Gejyo, F., 525
Gentil, M. A.., 2:E7
Gentile, S., 862
George, A. J. T., 1162
George, J. C., 12
Georgiou, T., 24
Gersualdo, L., 776
Giannopoulou, I., 469
Gladziwa, U., 1206
Goffin, E., 737
Göggelmann, C., 2:E10
Goh, J., 600
Goh, Y. I., 843
Gohda, T., 1255
Goldsmith, D. J. A., 1113
Goldstein, M. B., 1231
Golper, T. A., 556
Gömez, X., 60
González-Roncero, F. M., 2:E7
Gorban-Brennan, N., 1278
Goto, T., 36
Grabensee, B., 862
Grandaliano, G., 776
Graninger, W., 415
Greco, P., 776
Greco, R., 1176
Greene, P., 513
Greene, T., 920
Greer, J. W., 796
Griffin, V., 1226
Gröne, H.-J., 2:E11
Grönnenberg, R., 854
Grossman, R., 3:E16
Grünfeld, J.-P., 2:E6
Grupp, C., 2:E11
Guh, J.-Y., 1245
Guida, B., 266
Güngen, Y., 347
Gutierrez, J. M., 1078

Ha, I. S., 1001
Haas, M., 580, 1168
Haase, J., 2:E11
Haberal, M., 347
Hafeez, A., 930
Halldén, G., 854
Hallermann, C., 2:E11
Hamano, K., 695
Hammel, J., 1047
Han, D. C., 1
Hannah, E. L., 549
Hara, M., 706
Hara, S., 571, 706
Hartschuh, W., 1:E5
Haskell, W., 257
Hata, A., 1032
Havranek, E. P., 3:E17
Hawker, G. A., 843
Hayakawa, M., 3:E15
Hayasaka, K., 36
Hayasaka, T., 127
Hayashi, K., 1032
Hayashi, M., 392
He, J., 460

Heimbürger, O., 274, 422
Helmchen, U., 28
Henao, J., 1313
Hendra, K. P., 1307
Herman, W. H., 445
Hewan-Lowe, K., 1313
Hiatt, W. R., 76
Hiejima, Y., 1032
Hill, P., 24
Hirakata, H., 1:E4
Hirakawa, M., 1:E4
Hirano, N., 3:E12
Hirayama, H., 1032
Hiroshige, K., 937
Hisamuddin, I., 1313
Ho, K. K. L., 401
Hoeben, H., 102
Hoeks, A. P. G., 1206
Hoffman, R. M., 1068
Hogan, S. L., 297
Hollenstein, U., 415
Hong, C. D., 342
Hori, M., 948
Horikoshi, S., 1255
Hörl, M. P., 227
Hörl, W. H., 227, 415
Hoshimoto, K., 392
Hotta, O., 493
Hou, S., 930
Houlihan, C. A., 1183
Hoy, W. E., 679
Hruz, P., 3:E18
Hshieh, P., 1011
Huang, J.-J., 744
Huang, S.-C., 1245
Huber, G., 3:E18
Hudkins, K. L., 876
Hughson, M. D., 679
Hull, W. E., 2:E10
Humes, H. D., 1078
Hurtado, A., 1135
Hurtado, M.-E., 1135
Hutchinson, T., 1196
Hutson, A. D., 12
Hwang, W., 116
Hypolite, I. O., 1011

Ikeda, K., 503
Ikeda, T., 291
Ikeda, Y., 1292
Ikeuchi, H., 174
Imai, E., 948
Imanishi, Y., 1261
Inaba, M., 1261
Inaba, N., 392
Inada, Y., 937
Inoue, S., 571
Iseki, K., 189
Ishimura, E., 1261
Israni, A., 3:E16
Ito, A., 937
Ito, S., 475
Itoh, K., 36
Itoh, Y., 36
Iwano, M., 695
Iwasaki, Y., 525
Izumi, M., 948
Izzedine, H., 730

Jaber, B. L., 1307
Jabs, K., 433
Jacobson, S. H., 854
Jamal, S. A., 843
Jamerson, K., 513
Jansen, M., 415
Jansen, M. A. M., 108
Jayne, D. R. W., 42
Jefferson, J. A., 1135
Jekel, J., 1278
Jeon, R.-W., 55
Jerums, G., 1183
Jobes, D. V., 1102
Jogestrand, T., 274
Johnson, A. M., 1127
Johnson, C. A., 1270
Johnson, K., 679
Johnson, M. E., 828
Johnson, N. D., 966
Johnson, R. J., 1135
Jones, C. A., 445
Jones, C. H., 872
Jones, C. P., 445
Jornet, A. R., 60
Joy, M. S., 297
Jung, H. R., 1001

Kaimori, J.-Y., 948
Kaizu, K., 937
Kalenga, K., 737
Kalman, S., 1323
Kalra, P. A., 1153
Kamochi, M., 937
Kanagasundaram, N. S., 1047
Kanai, H., 1:E4
Kaneda, F., 1040
Kaneko, I., 392
Kaneko, Y., 174
Kanwar, Y. S., 3:E19
Kashif, M. A., 1300
Kashiwagi, M., 1:E4
Kasiske, B. L., 193, 762
Katafuchi, R., 503
Katori, H., 3:E15, 571
Katz, I. J., 3:E13
Kawabata, I., 36
Kawabata, M., 1032
Kawaguchi, A., 127
Kawaguchi, Y., 525
Kawakami, T., 36
Kazama, J. J., 525
Kehrli, M. E., Jr., 587
Kelly, J. J., 369
Kelly, J. P., 1135
Keough-Ryan, T., 1196
Khang, S., 159
Khositseth, S., 383
Kielstein, R., 637
Kim, C. Y., 165
Kim, G.-H., 55
Kim, H.-K., 55
Kim, J.-C., 55
Kim, M., 1261
Kim, M.-K., 1143
Kim, S. B., 342, 1213
Kimmel, P.L., 1236
Kirpekar, R., 1143
Klag, M. J., 324
Klaushofer, K., 580
Kleinoeder, T., 2:E11
Kletzmayr, J., 580
Knight-Gibson, C., 67
Kobayashi, K., 189
Kobayashi, T., 3:E15
Kochinda, T., 189
Koga, Y., 1:E4
Kohno, S., 695
Komine, N., 159
Komine, Y., 189
König, W., 972
Konings, C. J. A. M., 1206
Koo, J.-R., 55
Kooman, J. P., 1206
Korevaar, J. C., 108
Kornet, L., 1206
Koskas, F., 730
Kostadinov, S., 6:E23
Kouji, H., 1040
Kovac, J. A., 1236
Krämer, B. K., 28
Kramer, G., 48
Krantz, M. J., 3:E17
Kraus, J., 972
Krediet, R. T., 108, 862
Kubo, A., 695
Kumar, A., 165, 1226
Kumeda, Y., 1261
Kuroiwa, T., 174
Kurokawa, K., 525
Kurtz, I., 4:E1
Kusek, J., 920
Kusek, J. W., 245, 445, 513
Kushner, R. F., 154
Kutner, N. G., 1018
Kuypers, D., 315
Kuzuhara, K., 571
Kwan, J. T. C., 42

Lai, K.-B., 1061
Lai, Y.-H., 1245
Lam, C. W. K., 600
Lama, G., 958
Landry, M. L., 1102
Lavenne-Pardonge, E., 737

Lawson, J. A., 369
Lazaris, A. C., 469
Lee, S. K., 342, 1213
Lee, W.-L., 539
Lehnert, T., 1:E5
Leko-Mohr, Z., 580
Leung, C.-B., 1287
Leung, J., 245
Leunissen, K. M. L., 1206
Leutner, M., 713
Level, B., 513
Leverson, G. E., 1088
Levey, A. S., 146, 324, 920
Levin, N. W., 116
Levine, D. Z., 659
Levy, J. B., 1162
Lewis, J. B., 146
Lewis, R. R., 1190
Li, P. K.-T., 401, 600, 1054, 1061, 1287
Liangos, O., 1047
Lightstone, L., 1162
Lin, S.-H., 3:E14
Lin, Y.-F., 3:E14
Linas, S., 1:E1, 3:E17
Lindholm, B., 422
Lindner, A., 134
Little, M. A., 86
Liu, H.-L., 744
Locker, G. J., 48
Lopes, A. A., 533
Löw, R., 3:E18
Lowder, C. A., 549
Lui, S. F., 401, 600
Lundahl, J., 854
Luongo, I., 958
Luyckz, V. A., 3:E13
Lynch, P., 3:E19

MacCluer, J. W., 358
MacGibbon, B., 1196
Machet, D., 24
MacKay, S. M., 1078
Mac-Moune Lai, F., 401
Mactier, R. A., 308
Mader, R., 48
Maes, B., 315
Maezawa, A., 174
Mahmud, E., 813
Mahnensmith, R., 102
Mahuren, J. D., 134
Maidment, G., 1162
Maillard, M., 1135
Maiorano, E., 6:E22
Maiorca, R., 850
Makino, H., 3:E12
Makita, Y., 1032
Makoff, R., 245
Maksud, P., 730
Mallea, M. C., 549
Mallet, A., 730
Malovrh, M., 1218
Mamtora, H., 1153
Mann, D., 1096
Manno, C., 6:E22
Manno, S., 1040
Manzoor, F., 1226
Marberger, M., 48
Marcus, R. J., 1300
Markowitz, G. S., 892, 1118
Maroni, B., 245
Marrades, R. M., 1025
Marsh, J. V., 324
Marshall, M. R., 556
Martin, A. A., 324
Martin, M., 60, 594
Marzano, L., 266
Masakane, I., 36
Masanés, F., 1025
Masterson, T. M., 419
Masutani, K., 1:E4
Mateos, J., 2:E7
Mathew, T. H., 354
Matsunaga, A., 36
Matsushita, H., 3:E15, 706
Matsuzawa, N., 1040
Mayr, M., 3:E18
Mazzucco, G., 713
McCall, D., 689
McCarthy, J., 1270
McClellan, W., 796
McDougall, J. G., 1231
McFann, K. K., 1127
McGovern, T. F., 609
McNamara, A., 653
McQuillan, G., 920
McRae, J., 24
Mehta, H. K., 1231
Mehta, R. L., 616, 813
MemiS, L., 1323
Memoli, B., 266
Messiaen, T., 315
Mestre, M., 5:E21
Meyer, K. B., 324
Michail, S., 469
Michel, P., 2:E6
Mikhael, N., 1300
Miller, B. W., 828
Mimura, O., 291
Min, W. K., 342, 1213
Minutolo, R., 266
Miró, O., 1025
Miskulin, D. C., 324
Mitaka, T., 174
Miura, M., 525
Mix, T. C., 653
Miyazaki, M., 695
Modak, S., 165
Moeckel, G. W., 433
Monga, G., 713
Monno, R., 776
Montanyà, X., 60
Moore, G., 257
Morgan, C., 283
Morgan, S. H., 1162
Morita, A., 291
Movilli, E., 850
Mubin, T., 1300
Mulec, H., 67
Mullaney, S., 813
Müller, G. A., 2:E11
Müller, R., 972
Murase, T., 3:E15
Murata, G. H., 1068
Muratani, H., 189
Muray, S., 60
Murphy, B., 24
Myll, J., 257

Nachman, P. H., 297
Nagahama, K., 3:E15, 706
Nagasawa, T., 1040
Nagasawa, Y., 948
Nagasue, K., 1261
Nakajima, H., 948
Nakamura, S., 1:E4
Nakamura, T., 1032
Nakanishi, K., 3:E15
Nakatani, T., 1261
Nakayama, M., 503
Nakopoulou, L., 469
Narasimhan, N., 549
Narayan, K. M. V., 445
Narva, A. S., 358
Nash, K., 930
Naudeer, S., 1162
Neiberger, R. E., 12
Neumann, K. H., 972
Nghiem, D. D., 1300
Nichols, D. H., 828
Ninomiya, T., 1:E4
Nishiki, K., 127
Nishitani, Y., 695
Nishizawa, Y., 1261
Noh, J.-W., 55
Nojima, Y., 174
Novak, L., 92
Numakura, C., 36
Núñez, J., 594
Nunziata, R., 407
Nzerue, C. M., 1313

Oberbauer, R., 208, 580
Occhiogrosso, G., 6:E22
Odawara, M., 3:E15
O'Donoghue, D. J., 1153
Ogden, L. G., 460
Oglevie, S. B., 813
O'Hare, A., 203
Ohkura, T., 392
Ohta, T., 1261
Ohtaka, A., 475

Okada, S., 3:E12
Okechukwu, C. N., 533
Okubo, M., 3:E15
Okuno, S., 1261
Oliveras, A., 60
Olson, J. L., 203
O'Neill, W. C., 663
Onuigbo, M. A., 1096
Ootaka, T., 475
Ornt, D., 146
Osajima, A., 937
Oshiro, S., 189
O'Sullivan, A. J., 369
Ota, Y., 392
Owen, W., 195
Owen, W. F., Jr., 796
Özdemir, B. H., 347
Özdemir, F. N., 347
Özkaya, O., 1323

Paganini, E. P., 1047
Painter, P., 257
Pajouh, M., 1047
Pals, S. T., 407
Panesar, A., 1190
Pang, M. M. H., 721
Pankewycz, O., 3:E16
Pannu, N., 616
Paranandi, L., 245
Parikh, C. R., 689
Park, H. W., 1001
Park, J. S., 342, 1213
Patel, S. S., 1236
Paul, S., 257
Pecci, G., 1176
Peeters, J., 862
Perazella, M. A., 102
Pereira, P., 2:E7
Pérez-Fontán, M., 337
Perkins, L. A., 12
Persu, A., 737
Pertica, N., 850
Pervez, A., 824
Peterson, R. A., 1236
Phillips, A. O., 985
Phillips, W., 257
Picarelli, A., 1176
Pierucci, A., 1176
Pinkus, G. S., 183
Pirsch, J. D., 1088
Plaisance, M., 1113
Ploth, D. W., 769
Plum, J., 862
Poole, D., 245
Poon, P., 1061
Port, F. K., 533
Postiglione, L., 266
Poveda, R., 5:E21
Powe, N. R., 116, 324
Prabhakar, S. S., 195
Primack, W., 1310
Pusey, C. D., 1162
Pylypchuk, G. B., 834

Rabb, H., 587
Racadio, J., 966
Radinahamed, P., 383
Rahman, M., 1226
Rama, I., 5:E21
Rauchenwald, M., 48
Real, M. I., 60
Regele, H., 415
Rengelshausen, J., 2:E10
Rennke, H. G., 183
Rensma, P. L., 1206
Resta, L., 776
Reynolds, J. C., 1:E3
Ribeiro Alves, M. A. V. F., 1:E2
Richard, S., 2:E6
Richardson, R., 843
Rigby, R. J., 283
Riley, S. G., 985
Ritz, E., 1:E5
Roberts, T. L., 784
Roca, J., 1025
Rocco, M. V., 146, 245, 796
Rocha, J. L., 2:E7
Rodriguez-Algarra, G., 2:E7
Rodríguez-Carmona, A., 337
Rosales, M., 337
Roschger, P., 580
Rossini, M., 6:E22
Roth, D., 2:E9
Roxe, D. M., 154
Russ, G. R., 354
Russo, L. M., 899
Ryschkewitsch, C. F., 1102

Saab, P., 721
Sabbatella, L., 1176
Sadler, J. H., 116
Saheki, T., 189
St. Peter, W. L., 784
Saionji, K., 1032
Saito, T., 127, 475
Sakiewicz, P. G., 1047
Sala, E., 1025
Salama, A. D., 439, 1162
Salem, M., 6:E24
Salive, M., 445
Salsano, M. E., 958
Saltissi, D., 283
Sampath, L., 165
Samuelsson, O., 67
Sánchez, S., 594
Sandler, R. H., 6:E24
Sasaki, T., 174
Sass, H.-M., 637
Sato, H., 475, 695
Sato, K., 291
Sato, T., 475
Sawa, N., 571
Sayegh, M. H., 439
Scanlon-Kohlroser, C. A., 1310
Scavini, M., 358
Schena, A., 776
Schena, F. P., 776, 6:E22
Schmaldienst, S., 415
Schmidinger, M., 48
Schnitzler, M. A., 828
Schoene, R. B., 1135
Schollmeyer, P., 28
Schreiner, G. F., 1135
Schrier, R. W., 689, 1127
Schwarz, C., 580
Schwenger, V., 2:E10
Scolari, F., 850
Segawa, K., 937
Segerer, M., 876
Segerer, S., 876
Seifert, T., 1047
Self, S. E., 769
Selvaggi, L., 776
Senecal, M., 1196
Servilla, K. S., 1068
Sesso, R., 805
Sethi, S., 183
Shah, V. O., 358
Shaknovich, R., 892
Shapiro, L., 6:E23
Sharma, K., 486
Shaver, M. J., 556
Shibata, K., 1292
Shigematsu, T., 525
Shiiki, H., 695
Shikata, K., 3:E12
Shirato, I., 1255
Shoji, T., 1261
Shou, I., 1255
Shu, K.-H., 539
Shurrab, A. E., 1153
Sibley, R. K., 1143
Sietsema, K. E., 76
Simenauer, L., 6:E24
Simmons, W. D., 1088
Simonetti, B. M., 1176
Siva, S., 486
Smith, M. C., 1226
Smith, S., 1270
Soejima, A., 1040
Sokol, K., 165
Sollinger, H. W., 1088
Soma, J., 475
SöylemezoGlu, O., 1323
Spital, A., 611
Spitzer, A., 625
Stack, A. G., 533
Stacpoole, P. W., 12
Stallone, G., 776
Stathakis, C. P., 469
Steger, G. G., 48
Stehman-Breen, C., 134
Stein, P., 203

Steinman, T. I., 653
Stenvinkel, P., 274, 422
Stevenson, K. B., 549
Stidley, C. A., 358
Stillman, I. E., 653
Stitchantrakul, W., 383
Stoff, J. S., 1310
Stoner, G. L., 1102
Stoves, J., 872
Strippoli, G. F. M., 6:E22
Strom, J. A., 1307
Struijk, D. G., 862
Sugimoto, K., 127
Sumori, K., 392
Sung, J.-M., 744
Sureshkumar, K. K., 1300
Suzuki, M., 36
Suzuki, T., 36
Swenson, E. R., 1135
Szeto, C. C., 401, 1054
Szeto, C.-C., 1061, 1287
Szeto, C. Y.-K., 1061

Tabata, T., 291
Tabernero, J. M., 594
Tagami, T., 571
Tago, K., 1032
Taguma, Y., 493
Tajiri, M., 1032
Takagi, C., 174
Takagi, I., 937
Takakuwa, Y., 1040
Takano, H., 1032
Takase, S., 3:E12
Takemoto, F., 571
Takenaka, M., 948
Takishita, S., 189
Takizawa, f., 1292
Tana, T., 189
Tanaka, H., 503
Tanaka, S., 3:E15
Taneda, S., 876
Tang, N. L. S., 401
Tapaneya-olarn, W., 383
Tarng, D.-C., 2:E8
Terrin, N., 324
Tetta, C., 266
Thamer, M., 116
Theriaque, D. W., 12
Thomas, M. C., 354
Thylén, P., 854
Tirino, G., 958
Tiu, A. B., 1:E3
To, K. F., 401
Tochikubo, O., 1292
Tokita, Y., 1292
Tokuyama, T., 291
Tomino, Y., 1255
Tomioka, S., 493
Torregrosa, J. V., 1025
Tranaeus, A., 862
Traynor, J. P., 308
Trivedi, H. S., 721
Troche, I., 2:E11
Troidle, L., 1278
Tsalamandris, C., 1183
Tseng, C.-C., 744
Tsuda, E., 525
Tsukada, Y., 174
Tsukinoki, T., 3:E12
Tsuruoka, S., 127
Tune, B. M., 1143
Tuttle, K. B., 1321
Tveit, D. P., 1011
Tzamaloukas, A. H., 1068

Ubara, Y., 571, 706
Ueda, M., 1261
Ueda, Y., 392
Ueki, K., 174
Um, E. Y., 1001
Umemura, S., 1292
Uno, M., 392
Uriu, K., 937
Uyama, H., 695

Valdés, F., 337
Van Cangh, P. J., 737
Van den Berg, F M., 407
Van den Heuvel, H., 3:E13
Van der Sande, F. M., 1206
Van Lente, F., 920
Vanrenterghem, Y., 315
Vanwalleghem, J., 315
Van Wyck, D. B., 426
Vasandani, G., 1313
Vera, M., 60
Verger, C., 862
Vlietinck, A. J., 3:E13
Volpe, P., 776

Wada, J., 3:E12
Wagner, P. D., 1025
Wagnild, J. P., 549
Waldek, S., 1153
Walshe, J. J., 86
Walter-Sach, I, 2:E10
Wang, A. Y. M., 600
Wang, C.-L., 539
Wang, S.-R., 513
Ward, J. W., 203
Watanabe, H., 937
Watanabe, Y., 3:E12
Wead, L. M., 159
Weening, J. J., 407
Weir, M. R., 753, 1096
Weiss, B., 146
Weiss, L., 67
Weitzel, W. F., 1078
Welch, P. G., 1011
Wells, L., 872
Welty, T. K., 358
Wen, M., 876
Wener, M. H., 1135
Wenzel, C., 48
Wesson, D. E., 376
West, D., 513
Westhuyzen, J., 283
Westover, A. J., 1078
Whelton, P. K., 460
Wiesel, M., 1:E5
Wisnieski, J. J., 203
Wolf, G., 1
Wolfe, R. A., 533
Wong, P. W., 6:E24
Wong, T. Y. H., 401
Wong, T. Y.-H., 1054, 1061, 1287
Woodrow, G., 872
Woods, J. E., 3:E17
Work, J., 824
Wright, J. R., 1153
Wright, J. T., Jr., 1226
Wu, J.-J., 744
Wu, M.-J., 539
Wu, T.-H., 2:E8

Yamada, A., 571, 3:E15, 706
Yamasaki, Y., 3:E12
Yamazato, M., 189
Yan, G., 146
Yanase, T., 503
Yang, S.-S., 3:E14
Yang, W.-C., 2:E8
Yang, W. S., 342, 1213
Yano, K., 525
Yasuda, G., 1292
Yokota, M., 571
Yoon, J.-W., 55
Yorgin, P. D., 1143
Yoshida, Y., 695
Yoshino, T., 3:E12
Young, R. J., 679
Young, V. R., 195
Yousefzadeh, N., 1168
Yu, A. W. Y., 600
Yu, L. M., 600

Zager, P. G., 358
Zaman, F., 824
Zäuner, I., 28
Zeier, M., 1:E5
Zeis, P. M., 469
Zhang, R., 1018
Zibari, G., 824
Ziegler, T. W., 813
Zielinski, C. C., 48
Ziyadeh, F. N., 1
Zsontsich, T., 580

SUBJECT INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E and a number.
Page references to Supplement 1 (February 2002) and Supplement 2 (May 2002) are preceded, respectively, by S1: and S2:.

Access. *See* Vascular access
Accessory vein ligation, for salvage of poorly developed arteriovenous fistulae, 824–827
ACE inhibitors. *See* Angiotensin-converting enzyme inhibitors
ACR. *See* Albumin-creatinine ratio
Activator protein-1 binding, activation by low-density lipoprotein subclass B, 972–984
Acute interstitial nephritis
  celecoxib-induced, 1313–1317
  unusual presentation of, 653–658
Acute renal failure (ARF)
  celecoxib-induced in elderly diabetic, 1313–1317
  with Fanconi's syndrome and tonsil ulcerations after colloidal bismuth subcitrate intoxication, 3:E18
  hemodialysis-associated methemoglobinemia in, 1307–1309
  herbal remedy-associated, 3:E13
  hospital-acquired, 930–936
  low-efficiency dialysis, urea kinetics during, 556–570
  mechanical ventilation-induced, 616–624
  pediatric, with granulomas, 1323–1327
  renal tubule assist device for, 1078–1087
Acute tubular necrosis, hospital-acquired, 930–936
Acyclovir, for CMV infection, impact on kidney and kidney-pancreas transplantation, 1088–1095
Adhesion molecules
  activation by low-density lipoprotein subclass B, 972–984
  granulocyte recruitment at interstitial inflammation site and, 854–861
ADPKD. *See* Autosomal dominant polycystic kidney disease
Adrenalectomy, diagnosis of pheochromocytoma during, 2:E6
Adverse reactions, to iron therapy, 426–432
African American Study of Kidney Disease and Hypertension Trial, health-related quality of life and, 513–524
Age-related changes, in spot ACR prediction of albumin excretion rate, 1183–1189
Agrin, lack of proteinuria in GK rats after induction of anti-thy1 nephritis, 985–1000
Albumin, serum
  in hemodialysis patients
    biocompatibility of membranes and, 266–273
    in HEMO Study cohort at baseline, 245–256
    simvastatin and, 1213–1217
  reduction of extracellular fluid volume in peritoneal dialysis and, 872–875
  renal handling of, 899–919
Albumin, urinary. *See also* Albuminuria
  excretion rate prediction by spot ACR, age-related changes in, 1183–1189
  normal excretion of, S1:50–51
  untimed concentrations, microalbuminuria and, 445–459
Albumin-creatinine ratio (ACR)
  age and sex-adjusted cutoff values for, 1183–1189
  microalbuminuria prevalence in U.S., 445–459
  prediction of microalbuminuria, age-related changes in, 1183–1189
Albuminuria
  definition of, S1:50
  mechanisms of, 899–919
  in normotensive pregnancy and preeclampsia, 392–400
  prevalence in U.S., 445–459
Alcohol exposure, during pregnancy, congenital renal agenesis and, 689–693
Alkaline phosphatase, in hemodialysis patients, 291–296
Allograft
  chronic nephropathy risk, pretransplant C-reactive protein and, 1096–1101
  late failure, decline in inverse serum creatinine as predictor of, 762–768
  rejection, neovascularization induction, macrophages and lymphocytes in, 347–353
Alport's syndrome, pretransplant, 769–775
Altepace, for tunneled hemodialysis catheter dysfunction, 86–91
Altitude, high, polycythemia of, hyperuricemia, hypertension and proteinuria and, 1135–1142
ANCA. *See* Antineutrophil cytoplasmic autoantibody
Anemia
  in chronic kidney disease, 426–432
  glomerular filtration rate and, 120–127, S1:29
  management
    with erythropoietin, predialysis *vs.* postdialysis hemocrits for, 850–853
    impact of NKF-DOQI guidelines on, 784–795
Angiogenesis induction, tubulointerstitial injury and mononuclear cell infiltration in, 347–353
Angiography, *vs.* intravascular ultrasound for hemodialysis access assessment, 813–823
Angiomyolipomas, reduction of postembolism syndrome after ablation, 966–971
Angiotensin-converting enzyme, serum activity, prognostic role in type 2 diabetic patients on CAPD, 1054–1060
Angiotensin-converting enzyme inhibitors (ACE inhibitors)
  with angiotensin II receptor blocker, effect on plasma and kidney angiotensin II levels, 159–164
  effects on hemoglobin, circulating erythropoietin and IF-1, 600–608
  for hemodialysis-associated hypertension, 227–244
  in proteinuric nephropathy, TGF-β1 production and, 486–492
Angiotensin II, effect of ACE inhibitor with angiotensin II receptor blocker on, 159–164

Angiotensin II receptor blockers
with ACE inhibitor, effect on plasma and kidney angiotensin II levels, 159–164
effects on hemoglobin, circulating erythropoietin and IF-1, 600–608
Angiotropic large cell lymphoma, case study, 892–895
Anticoagulation, for hemodialysis with calcium-containing dialysate, 315–323
Antiendomysial antibodies, in Berger's disease, 1176–1182
Antiglomerular basement membrane antibody absence, in Goodpasture's disease, 1162–1167
Antiglomerular basement membrane disease
in pulmonary renal syndrome, 42–47
in transplant recipients with Alport's syndrome, 769–775
Antihypertensive drugs
mechanism of albuminuria reduction, 899–919
usage during hemodialysis, exercise effects on, 828–833
Antimicrobial-impregnated peritoneal dialysis catheters, for exit-site infection prevention, 165–173
Antineutrophil cytoplasmic autoantibody (ANCA)
negativity in vasculitis with systemic lupus erythematosus, 433–438
in pediatric periglomerular granulomatous reaction, 1323–1327
vasculitis, in pulmonary renal syndrome, 42–47
Antioxidants
decreased serum activity in hemodialysis patients, markers for, 1040–1046
relationship to serum creatinine, 460–468
Antiphospholipid syndrome, in African-American girl, 433–438
Antirheumatic agents, membranoproliferative glomerulonephritis development and, 706–712
Aortic aneurysms, effects of stent-grafting crossing renal artery ostia, 730–736
Apolipoproteins
in chronic renal failure, fluvastatin effect on, 67–75
E2 variant, without lipoprotein glomerulopathy, 3:E15
in hypercholesterolemic chronic renal dialysis patients, lipid-lowering therapy for, 283–290
ARF. *See* Acute renal failure
L-Arginine-nitric oxide pathway, in end-stage renal disease, 195–201
Arginine vasopressin receptor type 2, intrafamilial phenotype variability in nephrogenic diabetes insipidus, 737–743
Aristolochic acid-induced Fanconi's syndrome, with nephropathy, presenting as hypokalemic paralysis, 3:E14
Arrhythmia, as cause of death in ESRD, 146–153
Arterial distensibility, in chronic renal failure, 1206–1212
Arteriosclerotic renovascular disease, renal functional outcome and mortality determinants in, 1153–1161
Arteriovenous fistulae
native
preoperative evaluation of, 1218–1225
upper-arm, long-term survival of, 92–101
NKF-DOQI guidelines, impact of, 784–795
nonmaturing, salvaging by percutaneous ligation of accessory veins, 824–827
Arteriovenous graft, *vs.* native upper-arm fistula, long-term survival of, 92–101
Ascorbic acid, relationship to serum creatinine, 460–468
Atherosclerosis
with persistent elevated CRP in CAPD patients, 342–346
in renal artery stenosis
outcome prediction for PTRA, 60–66
parenchymal injury as determinant of outcome in, 1321–1322
Autopsy study, of glomerular tip lesion in minimal change nephropathy, 1168–1175
Autosomal dominant polycystic kidney disease (ADPKD)
genetic testing, ethics of, 637–652
relationship of renal volume growth and renal function in, 1127–1134
renal transcatheter arterial embolization for, 571–579

Bacteremia, impact of NKF-DOQI on, 549–555
Bacterial biofilm, infection patterns in chronic peritoneal dialysis and, 1278–1286
B-cell lymphoproliferative disorder, crystal-storing histiocytosis of kidney in, 183–188
Berger's disease, antiendomysial antibodies in, 1176–1182
Bicarbonaturia, in congenital lactic acidosis, 12–23
Biocompatibility
of hemodialysis membranes, serum albumin changes and, 266–273
of vitamin E-bonded hemodialyzer, 127–133
Bioelectrical impedance analysis, reproducibility of TBW estimates, 154–158
Bioenergetics, mitochrondrial respiratory chain function in CRF, 1025–1031
Birth certificate data, for congenital renal agenesis case-control analysis, 689–693
Bismuth subcitrate intoxication, acute renal failure with Fanconi's syndrome and tonsil ulceration after, 3:E18
BK virus regulatory region rearrangements, in leukemia with tubulointerstitial nephritis and meningoencephalitis, 1102–1112
Blood flow rate
extracorporeal, in continuous venovenous hemodialysis, 1047–1053
preoperative, of native arteriovenous fistulae, 1218–1225
prescribed *vs.* actual in chronic hemodialysis, correction of, 1231–1235
Blood pressure
ambulatory systolic changes, TGFβ-1 urinary excretion and, 486–492
in chronic hemodialysis, effect of needle gauge on, 1231–1235
exercise capacity in ESRD and, 76–85
in hemodialysis-associated hypertension, 227–244
in high-altitude polycythemia, 1135–1142
measurements, standard *vs.* "usual" in hemodialysis patients, 1226–1230
renal function decline in type 2 diabetic nephropathy and, 376–382
Body composition, in chronic renal failure, 369–375
Body weight deficits, in continuous ambulatory peritoneal dialysis, 1068–1077
Bone disease, glomerular filtration rate and, S1:143–155

Bone metabolism, in hemodialysis patients, 291–296
Bone mineral density (BMD)
in chronic renal failure, 369–375
in hemodialysis patients, 291–296
osteoprotegerin and PTH as markers for, 580–586
inability to identify dialysis-dependent renal failure patients with fractures, 843–849
Bone turnover disease, in diabetic hemodialysis patients, impaired PTH secretion and, 1261–1269
Bovine model, of hemodialysis-induced neutropenia, 587–593
Brachiocephalic fistula, long-term survival of, 92–101
Brain BK virus regulatory region rearrangements ,in leukemia with tubulointerstitial nephritis and meningoencephalitis, 1102–1112
Bucillamine, membranoproliferative glomerulonephritis development and, 706–712
Burden, of hemodialysis caregivers, 805–812

Cadaveric donors, universal conscription for, 609–615
Calcaneal ultrasound, inability to identify dialysis-dependent renal failure patients with fractures, 843–849
Calcium, in hemodialysis patients, 291–296
Calcium metabolic disorders, glomerular filtration rate and, S1:143–155
Calcium oxalate, urinary saturations in pediatric renal tubular acidosis, 383–391
Calcium phosphate, urinary saturations in pediatric renal tubular acidosis, 383–391
Calcium-to-creatinine ratio, for monitoring potassium citrate supplementation, 383–391
CAPD. *See* Continuous ambulatory peritoneal dialysis
Cape aloes, acute renal failure associated with, 3:E13
Capecitabine, for metastatic renal cell carcinoma after failed immunotherapy, 48–54
Captopril, effect on angiotensin II plasma and kidney tissue levels, 159–164
Cardiac output, intradialytic, midodrine *vs.* cool dialysate, 102–107
Cardiac tamponade, with malignant hypertension, 3:E17
Cardiovascular disease, chronic kidney disease and, S1:204–212
Caregivers, for hemodialysis patients, burden and quality of life for, 805–812
Carnitine, exercise capacity in ESRD and, 76–85
Carotid artery atherosclerosis progression, elevated interleukin-6 and, 274–282
Case-control study, of congenital renal agenesis, 689–693
Catabolic illness, body weight deficits in continuous ambulatory peritoneal dialysis and, 1068–1077
Catenins, in glomerulonephritis, 469–474
Catheter malfunction, repeated alteplase usage for, 86–91
CD11b/CD18 expression, granulocyte recruitment at interstitial inflammation site and, 854–861
CD44 expression, in immunoglobulin A nephropathy, 407–414
CD62L, granulocyte recruitment at interstitial inflammation site and, 854–861
Celecoxib-induced acute interstitial nephritis, 1313–1317
Celiac disease, common pathogenic pathway with IgA nephropathy and, 1176–1182
Cell adhesion kinase β expression, in crescentic glomerulonephritis, 174–182
Central blood volume, intradialytic, midodrine *vs.* cool dialysate, 102–107
Cerebral lymphoma, primary, with membranous nephropathy, 6:E22
Cerebrospinal fluid BK virus regulatory region rearrangements, in leukemia with tubulointerstitial nephritis and meningoencephalitis, 1102–1112
Children
case studies, renal failure with granulomas, 1323–1327
microalbuminuria prevalence and, 445–459
nephrotic syndrome, T-lymphocyte populations and cytokines in, 958–965
with RTA, potassium citrate dosage for urinary abnormality correction, 383–391
with systemic lupus erythematosus and ANCA-negative renal vasculitis, 433–438
Chlamydia pneumoniae seropositivity, interleukin-6 elevation and, 274–282
Chloramine toxicity, in maintenance hemodialysis patients, 1307–1309
Chlorhexidine, peritoneal dialysis catheter impregnation, effects of, 165–173
CHOICE Study, modality selection in incident dialysis patients, case-mix differences in, 324–336
Cholesterol. *See also* Hypercholesterolemia
in ESRD, vitamin E-bonded hemodialyzer and, 127–133
high-density, diet *vs.* simvastatin for, 283–290, 419–421
low-density. *See* Low-density lipoprotein
Chronic allograft nephropathy
decline in inverse serum creatinine as predictor of, 762–768
risk, pretransplant C-reactive protein and, 1096–1101
Chronic kidney disease
cardiovascular disease and, S1:204–212
classification/stages of, 37–42, S1:18–20
background for, S1:46–47
clinical applications, S1:63
implementation issues, S1:63
limitations of, S1:62–63
rationale for, S1:47–62
research recommendations, S1:63–64
clinical presentation, S1:105–110
complications, glomerular filtration rate and, S1:111
diabetic complications and, 198–203, S1:31
DOQI Work Group definition of, S1:18
early detection/intervention strategies, S1:33–34
evaluation/treatment of, S1:43, S1:65–71
current status, S1:34–36
markers. *See also specific markers*
factors associated with loss of function, 170–197, S1:30–31
markers, S1:103–110. *See also specific markers*
modeling reciprocal of creatinine *vs.* time in, 753–761
outcomes, S1:43–44
prevalence, 42–43, S1:20–21
by stage, S1:54–56
as public health problem, 32–33, 37–45, S1:17
risk, 72–75, S1:43
treatment approach, using clinical practice guidelines, S1:215–222

Chronic renal failure (CRF)
in African Americans, health-related quality of life for, 513–524
arterial wall properties in, 1206–1212
body composition and energy metabolism in, 369–375
caregivers, burden and quality of life for, 805–812
definition of, S1:59
dialysis survival, dietary fish intake and, 1018–1024
hemodialysis exercise during, decreases antihypertensive drug usage, 828–833
lipid abnormalities, fluvastatin for, 67–75
osteoprotegerin circulating levels in, 525–532
pathogenesis, antioxidant vitamins and, 460–468
postdialysis urea, prediction using stop dialysate flow method, 308–314
progression despite ACE inhibition, TGF-β1 production and, 486–492
protein-energy malnutrition in, causes of, 422–425
from renal artery stenosis, outcome prediction for PTRA, 60–66
skeletal muscle mitochondrial function preservation in, 1025–1031
slowing progression of, 721–729
in type 2 diabetic nephropathy, cigarette smoking and, 376–382
vitamin B_6 metabolism and homocysteine levels in, 134–145
Cigarette smoking, renal function decline in type 2 diabetic nephropathy despite ACE inhibition, 376–382
Citrate anticoagulation, with calcium-containing dialysate, 315–323
Citrate-to-creatinine ratio, for monitoring potassium citrate supplementation for pediatric renal tubular acidosis, 383–391
Citrullinemia, adult-onset type II, long-term hemodialysis for, 189–192
Clinical practice guidelines
approach to chronic kidney disease with, S1:215–222
recommendations for, S1:213–214
Common carotid artery, wall characteristics, in chronic renal failure, 1206–1212
Comorbidity
modality selection in incident dialysis patients and, 324–336
renal function outcome in arteriosclerotic renovascular disease, 1153–1161
Complement-containing glomerular immune deposits, factor H-related protein-5 in, 24–27
Compliance, with hemodialysis prescription for ESRD, 1236–1244
Computed tomography, of renal volume growth in ADPKD, renal function and, 1127–1134
Congenital lactic acidosis, renal manifestations of, 12–23
Congenital renal agenesis, case-control analysis of birth characteristics, 689–693
Conjunctival calcification, in hemodialysis patients, 291–296
Constipation
infantile cystinosis presenting as, 6:E24
prevalence in CAPD *vs.* hemodialysis patients, 1292–1299
Continuing medical education exercises, 1:E1
Continuous ambulatory peritoneal dialysis (CAPD)
ACE serum activity prognostic role in type 2 diabetes mellitus, 1054–1060
Antimicrobial-impregnated catheter for infection control, 165–173
constipation prevalence *vs.* hemodialysis patients, 1292–1299
for hypercholesterolemic chronic renal dialysis patients, 283–290
for pediatric acute renal failure with granulomas, 1323–1327
reduction of extracellular fluid volume, effect on serum albumin, 872–875
weight deficits in, 1068–1077
Continuous positive airway pressure, renal function effects, 616–624
Continuous renal replacement therapy, for critical illness, urea kinetics during, 556–570
Continuous venovenous hemofiltration (CVVH)
for critical illness, urea kinetics during, 556–570
dialyzer fiber bundle volume and solute removal kinetics in, 1047–1053
failure to prevent death in paraquat poisoning, 55–59
Corneal calcification, in hemodialysis patients, 291–296
Cost
of ESRD, slowing progression of chronic renal failure and, 721–729
vs. quality of care in dialysis facilities, 116–126
C-reactive protein (CRP)
of hemodialysis patients, biocompatibility of membranes and, 266–273
high-sensitivity, effect of simvastatin in hemodialysis, 1213–1217
persistent elevation, with ischemic heart disease in CAPD patients, 342–346
pretransplant, risk of chronic allograft nephropathy in renal transplant recipients and, 1096–1101
Creatinine, serum
antioxidant vitamins and, 460–468
assay, calibration and random variation in, 920–929
elevated, microalbuminuria prevalence and, 445–459
hospital-acquired renal insufficiency morality and, 930–936
inverse decline, in predicting late allograft failure, 762–768
mechanical ventilation effects on, 616–624
renal function decline in type 2 diabetic nephropathy and, 376–382
Creatinine clearance
body weight deficits in continuous ambulatory peritoneal dialysis and, 1068–1077
in predicting late allograft failure, 762–768
Crescentic glomerulonephritis
E-cadherin/catenin complex expression in, 469–474
increased cell adhesion kinase β expression in, 174–182
in microscopic polyangiitis, spontaneous and protracted partial remission in, 1113–1117
CRF. *See* Chronic renal failure
Critical care
green urine and, 4:E20

hemodialysis-associated methemoglobinemia in ARF, 1307–1309
low-efficiency dialysis, urea kinetics during, 556–570
mechanical ventilation, renal function effects of, 616–624
Cross-sectional survey, of microalbuminuria, 445–459
Cryoglobulinemic glomerulonephritis, oral interferon-α therapy for, 876–888
Cubilin, albumin uptake from glomerular ultrafiltrate and, 899–919
Cuffed hemodialysis catheter, tunneled, alteplase for, 86–91
CVVH. *See* Continuous venovenous hemofiltration
Cyclophosphamide-associated neutropenia, pulmonary renal syndrome mortality and, 42–47
Cyclosporine, late allograft failure, decline in inverse serum creatinine as predictor of, 762–768
Cyclosporine-associated nephrotoxicity, in heart transplant recipients, tacrolimus for, 3:E16
Cystic fibrosis, asymptomatic, with hematuria in adult, 1:E3
Cytokines, in childhood nephrotic syndrome, 958–965
Cytomegalovirus infection, impact in kidney and kidney-pancreas transplantation, 1088–1095
Cyxlooxygenase-2 inhibitors, acute renal failure risk and, 1313–1317

Depression, of ESRD patients on chronic hemodialysis, 1236–1244
Diabetes insipidus, nephrogenic, intrafamilial phenotype variability in, 737–743
Diabetes mellitus
albumin excretion rate, spot albumin-creatinine ratio prediction of, 1183–1189
celecoxib-induced acute interstitial nephritis in, 1313–1317
complications in chronic kidney disease, 198–203, S1:31
constipation prevalence in CAPD *vs.* hemodialysis patients, 1292–1299
development of urinary tract infection caused by *E. coli* and, 744–752
glomerulosclerosis of, stereological features of, 678–688
in hemodialyzed patients, impaired PTH secretion in mechanism of low bone turnover, 1261–1269
maternal, congenital renal agenesis and, 689–693
microalbuminuria prevalence and, 445–459
renal structural changes, mesangial cell injury and macrophage influx, 985–1000
type 2
ACE serum activity prognostic role in CAPD, 1054–1060
different renal damage patterns in, 713–720
Diabetic renal disease
hemodialysis for, long-term glycemic control measurements and, 297–307
leptin and, 1–9
with myeloperoxidase-antineutrophil cytoplasmic antibody-associated glomerulonephritis, 1:E4
prevalence in Zuni Indians, 358–368
type 2 progression, cigarette smoking and, 376–382
Dialysate
calcium-containing, with regional citrate anticoagulation, 315–323
cool, intradialytic hemodynamics and, 102–107

Dialysis. *See also* Hemodialysis; Peritoneal dialysis
with ADPKD, renal transcatheter arterial embolization for, 571–579
care, improving outcomes and quality of, 889–891
chronic, pulmonary embolism risk in, 1011–1017
early initiation, effect on HRQOL, 108–115
end-stage renal disease prognostic factors, 1196–1205
initiation, glomerular filtration rate and, S1:61–62
Dialysis adequacy
dialyzer fiber bundle volume and solute removal kinetics in CVVH and, 1047–1053
impact of NKF-DOQI guidelines on, 784–795
Dialysis adequacy and transport test, for characterization of transport type in Chinese PD therapy patients, 1287–1291
Dialysis administrators, survey of dialysis facility cost-quality tradeoffs, 116–126
Dialysis facilities, cost-quality tradeoffs, 116–126
Dialysis Outcomes Quality Initiative (DOQI)
background, S1:32–36
chronic kidney disease
definition/stages, S1:23
evaluation and treatment, S1:23–24
risk, S1:24
development, review of evidence, S1:21–23
evaluation of, 108–115
evaluation/treatment, proteinuria assessment, S1:93–102
executive summary, S1:17–31
impact on clinical practice, USRDS evaluation of, 784–795
in improving outcomes and quality of dialysis care, 889–891
vascular access guidelines, predicting impact of, 549–555
Work Group
charge to, S1:17–18
chronic kidney disease definition, S1:18
members of, S1:238–242
Diet. *See* Nutrition
Direct hemoperfusion, with polymyxin B-immobilized fiber for endotoxin removal in septic shock, 937–947
Dogs, metabolic renal substitution therapy for uremia in, 1078–1087
DOQI. *See* Dialysis Outcomes Quality Initiative
Dual x-ray absorptiometry (DEXA), inability to detect fractures in dialysis-dependent renal failure patients, 843–849
Duplex sonography, preoperative, of native arteriovenous fistulae, 1218–1225

E-cadherin, in glomerulonephritis, 469–474
Economic factors, of ESRD, slowing progression of chronic renal failure and, 721–729
Effluent urea nitrogen to blood urea nitrogen ratio, in continuous venovenous hemodialysis, 1047–1053
Elderly, celecoxib-induced acute interstitial nephritis in, 1313–1317
Electrophoresis, of concentrated urine, 24-hour *vs.* random sampling, 1:E2
Enalapril, effects on hemoglobin, circulating erythropoietin and IF-1, 600–608

Encephalopathy, in citrullinemia, long-term hemodialysis for, 189–192
Endocrine neoplasia type IIB, in pyleonephritis with pheochromocytoma multisystem crisis, 6:E23
Endothelin-1, placental, pregnancy outcome in CsA-treated transplant recipients and, 776–783
Endotoxin removal, by direct hemoperfusion with polymyxin B-immobilized fiber in septic shock, 937–947
End-stage renal disease (ESRD)
  case-mix factors, modality selection and outcome, 324–336
  death notification classification systems, comparison of, 146–153
  definition of, S1:59–60
  dialysis facility cost-quality trade-offs, 116–126
  exercise capacity, clinical and demographic predictors of, 76–85
  glomerulosclerosis, glomerular size and, 678–688
  impact of NKF-DOQI guidelines on, 784–795
  L-arginine-nitric oxide pathway in, 195–201
  LDL subclass B from, modulation of endothelial cells, 972–984
  neutrophil function, vitamin E-bonded hemodialyzer and, 127–133
  outcomes, in fee-for-service plans *vs.* HMOs, 796–804
  oxidative stress, vitamin E-bonded hemodialyzer and, 127–133
  premature death, QTc dispersion for identification of, 834–842
  prevalence
    slowing progression of CRF and, 721–729
    in Zuni Indians, 358–368
  prognostic factors, 1196–1205
  protein-energy malnutrition in, causes of, 422–425
  in type 2 diabetes mellitus, renal function decline with cigarette smoking, 376–382
  vitamin B_6 metabolism and homocysteine levels in, 134–145
Energy intake, of HEMO Study cohort at baseline, 245–256
Energy metabolism, in chronic renal failure, 369–375
Epidemiologic study
  of end-stage renal disease prognostic factors, 1196–1205
  population-based, cross-sectional, of Zuni Indians, 358–368
EPO. *See* Erythropoietin
Erythrocyte membrane lipid peroxidation, decreased serum antioxidant activity in hemodialysis patients and, 1040–1046
Erythropoietin (EPO)
  for anemia of chronic kidney disease, 426–432
  circulating, in posttransplantation erythrocytosis, angiotensin II receptor antagonist and ACE inhibitor effects on, 600–608
  hematocrit normalization, effect on exercise capacity in hemodialysis patients, 257–265
  hemodialysis-associated hypertension and, 227–244
  recombinant human. *See* Recombinant human erythropoietin
Escherichia coli urinary tract infection, host and bacterial factors in, 744–752
ESRD. *See* End-stage renal disease
ESRD Clinical Performance Measures Project Annual Report for 2001
  appendices, S2:62–97
  background and project methods, s2:11–119
  executive summary, S2:4–10
  in-center hemodialysis patients
    adult, S2:20–38
    pediatric, S2:48–55
  list of tables and figures, S2:57–61
  peritoneal dialysis patients, adult, S2:39–48
Ethical issues, in genetic testing, 637–652
Ethnicity, microalbuminuria prevalence and, 445–459
Exercise
  during hemodialysis decreases antihypertensive drug usage, 828–833
  training effect on exercise capacity in hemodialysis patients, 257–265
Exercise capacity
  in ESRD, clinical and demographic predictors of, 76–85
  in hemodialysis patients, effects of exercise training and hematocrit normalization on, 257–265
Exit-site infection, prevention, antimicrobial-impregnated CAPD catheters for, 165–173
Extracellular fluid volume, in hemodialysis-associated hypertension, 227–244

Factor H-related protein-5, in human renal biopsy specimens, 24–27
Family planning, genetic disorders and, 637–652
Fanconi's syndrome
  with acute renal failure and tonsil ulcerations after colloidal bismuth subcitrate intoxication, 3:E18
  aristolochic acid-induced with nephropathy, presenting as hypokalemic paralysis, 3:E14
  in congenital lactic acidosis, 12–23
Fee-for-service plans, hemodialysis outcomes *vs.* HMOs, 796–804
Ferritin, serum, high, in chronic kidney disease, 426–432
Fiber, constipation prevalence in CAPD *vs.* hemodialysis patients, 1292–1299
Fiber bundle volume, in continuous venovenous hemodialysis, 1047–1053
Fibrosis, in allograft rejection, potentiation by mononuclear cell infiltration, 347–353
Fish oil, dialysis survival and, 1018–1024
Fluoropyrimidine carbamate, for metastatic renal cell carcinoma after failed immunotherapy, 48–54
5-Fluorouracil, pharmacokinetics in chronic hemodialysis patient, 2:E10
Fluvastatin, for lipid abnormalities in chronic renal failure, 67–75
Focal segmental glomerulosclerosis (FSGS)
  biological characterization of, 625–636
  collapsing, after pamidronate therapy, 1118–1122
  glomerular plasminogen activator inhibitor type I in, 695–705
  glomerular size and, 679–688
  glomerular tip lesion in, 1168–1175
  primary, early phenotypic change of glomerular podocytes in, 475–485

steroid-resistant, prediction of outcome with pulse methylprednisolone therapy, 1143–1152
Folate, plasma homocysteine levels in hemodialysis patients and, 1032–1039
Folic acid supplements, effects on vitamin B_6 metabolism and homocysteine levels in CRF, 134–145
Fracture detection, in dialysis-dependent renal failure patients, 843–849
FSGS. *See* Focal segmental glomerulosclerosis
Functional status, of ESRD patients on chronic hemodialysis, 1236–1244

Ganciclovir, for CMV infection, impact on kidney and kidney-pancreas transplantation, 1088–1095
Gender differences
in albumin-creatinine ratio, 1183–1189
in microalbuminuria prevalence, 445–459
in renal volume growth and renal function in ADPKD, 1127–1134
Genetic factors
in focal segmental glomerulosclerosis, 625–636
intrafamilial phenotype variability in nephrogenic diabetes insipidus, 737–743
in kidney disease, 637–652
polymorphisms
plasminogen activator inhibitor-1, peritoneal transport characteristics and, 1061–1067
and secondary hyperparathyroidism in hemodialysis patients, 1255–1260
Genetic testing, ethical issues in, 637–652
Glomerular filtration rate (GFR)
anemia and, 120–127, S1:29
bone disease and, S1:143–155
calcium metabolic disorders and, S1:143–155
in chronic kidney disease classification, S1:18–20
complications of chronic kidney disease and, S1:111
complications of kidney disease in adults, S1:27–29
in congenital lactic acidosis, 12–23
decreased
complications of, S1:44–45
with kidney damage, S1:56–59
without kidney damage, S1:48
dialysis initiation and, S1:61–62
estimation, serum creatinine assay calibration and, 920–929
estimation of
DOQI guidelines, S1:76–92
methodology using 24-hour urine samples, S1:236–237
hypertension and, 112–119, S1:29
indices of functioning and well-being, S1:29–30
indices of functioning/well-being and, S1:161–169
neuropathy and, S1:156–160
nutritional status and, 128–142, S1:29
phosphorus metabolic disorders and, S1:143–155
and renal volume growth in ADPKD, 1127–1134
Glomerulonephritis
constipation prevalence in CAPD *vs.* hemodialysis patients, 1292–1299
crescentic, increased cell adhesion kinase β expression in, 174–182
cryoglobulinemic, interferon-α for, 876–888
diabetic, different renal damage patterns in, 713–720
with diffuse pulmonary hemorrhage. *See* Pulmonary renal syndrome
E-cadherin/catenin complex in, 469–474
factor H-related protein-5 and, 24–27
glomerular plasminogen activator inhibitor type I in, 695–705
long-term prognosis, effects of initial history and plasmapheresis on, 28–35
myeloperoxidase-antineutrophil cytoplasmic antibody-associated with diabetic nephrosclerosis, 1:E4
rapidly progressive
in absence of circulating antiglomerular basement membrane antibodies, 1162–1167
long-term prognosis, effects of initial history and plasmapheresis on, 28–35
Glomerulosclerosis
development, leptin and, 1–9
diabetic, different renal damage patterns in, 713–720
glomerular size and, 679–688
Glomerulus
CD44 expression in immunoglobulin A nephropathy, 407–414
complement-containing immune deposits, factor H-related protein-5 in, 24–27
function, mechanical ventilation effects on, 616–624
plasminogen activator inhibitor type I in glomerulonephritis, 695–705
size, glomerulosclerosis and, 679–688
size selectivity of, 899–919
tip lesion, in minimal-change nephrotic syndrome, 1168–1175
Glucocorticoids, VEGF and proteinuria in proliferative glomerulonephritis and, 1001–1010
Glycemic control, long-term measurements for diabetic ESRD patients on hemodialysis, 297–307
Goodpasture syndrome
in absence of circulating antiglomerular basement membrane antibodies, 1162–1167
during course of Schönlein-Henoch purpura, 5:E21
Granulocytes, hemodialysis-activated, at interstitial inflammation site, 854–861
Granulomas, with pediatric acute renal failure, 1323–1327

Health Care Financing Administration (HCFA), cause of death compared with HEMO Study, 146–153
Health maintenance organizations (HMOs), hemodialysis outcomes *vs.* fee-for-service plans, 796–804
Health-related quality of life
in African American chronic renal failure patients, 513–524
early initiation of dialysis and, 108–115
Heart conduction problems, as cause of death in ESRD, 146–153
Heart transplant recipients, cyclosporine-associated nephrotoxicity, tacrolimus for, 3:E16
Hematocrit
NKF-DOQI guidelines, impact of, 784–795
normalization, effect on exercise capacity in hemodialysis patients, 257–265

predialysis *vs.* postdialysis hemocrits during erythropoietin therapy, 850–853
Hematomas, after kidney transplantation, ultrasonography of, 663–678
Hematuria
in acute interstitial nephritis, 653–658
in asymptomatic cystic fibrosis in adult, 1:E3
Hemodialysis (HD)
access. *See* Vascular access
anemia of chronic kidney disease, iron therapy for, 426–432
caregiver burden and quality of life for, 805–812
chronic
for adult-onset type II citrullinemia, 189–192
correction of discrepancy between prescribed and actual blood flow rates, 1231–1235
5-fluorouracil pharmacokinetics in, 2:E10
pulmonary embolism risk in, 1011–1017
for chronic renal failure, arterial wall properties and, 1206–1212
complications, impact of NKF-DOQI on, 549–555
constipation prevalence *vs.* CAPD patients, 1292–1299
death classification systems for ESRD, comparison of, 146–153
for diabetes mellitus, long-term glycemic control measurements and, 297–307
dialyzer fiber bundle volume and solute removal kinetics in, 1047–1053
effect of simvastatin on high-sensitivity CRP and albumin, 1213–1217
end-stage renal disease prognostic factors, 1196–1205
erythropoietin therapy, predialysis *vs.* postdialysis hemocrits during, 850–853
for ESRD, outcomes in HMOs *vs.* fee-for-service plans, 796–804
exercise capacity
effects of exercise training and HCT normalization in, 257–265
in ESRD and, 76–85
exercise during, decreases antihypertensive drug usage, 828–833
granulocyte recruitment at interstitial inflammation site and, 854–861
homocysteine plasma levels, methylenetetrahydrofolate reductase genotype and vitamin B_{12} effects on, 1032–1039
hypoparathyroidism in, risk factors and mortality risk of, 1245–1254
initiation, glomerular filtration rate and, S1:61–62
intestinal iron absorption, indirect evaluation of, 594–599
long-term survivors, mortality risk and characteristics of, 533–538
methemoglobinemia-induced by, with acute renal failure, 1307–1309
neutropenia from, CD11/CD18 adhesion molecule in, 587–593
NKF-DOQI guidelines, impact of, 784–795
osteoprotegerin in, 580–586
premature death, QTc dispersion for identification of, 834–842
preoperative duplex sonography of native arteriovenous fistulae, 1218–1225
reproducibility of bipedal bioelectrical impedance total body water estimates, 154–158
secondary hyperparathyroidism with parathyroid gene polymorphism in, 1255–1260
Hemodialysis catheters
malfunction
alteplase for, 86–91
repeated alteplase use for, 86–91
NKF-DOQI guidelines, impact of, 784–795
Hemodialyzers
membrane biocompatibility, serum albumin changes and, 266–273
vitamin E-bonded, neutrophil function and oxidative stress in ESRD, 127–133
Hemoglobin
A_1C, long-term control measurements in diabetic ESRD patients on hemodialysis, 297–307
in posttransplantation erythrocytosis, angiotensin II receptor antagonist and ACE inhibitor effects on, 600–608
Hemoperfusion, *vs.* CVVH for paraquat poisoning, 55–59
HEMO Study
baseline nutritional status of cohort, 245–256
cause of death compared with HCFA form, 146–153
Heparin, *vs.* regional anticoagulation, for hemodialysis with calcium-containing dialysate, 315–323
Hepatitis-C associated nephropathy, mimicked by lupus membranoproliferative glomerulonephritis, 3:E19
High-altitude polycythemia, hyperuricemia, hypertension and proteinuria in, 1135–1142
High-density lipoprotein, in chronic renal dialysis patients, diet *vs.* simvastatin for, 283–290, 419–421
Histology
of focal segmental glomerulosclerosis, 625–636
of primary immunoglobulin A nephropathy, progression and, 401–406
at time of diagnosis, prognosis for rapidly progressive glomerulonephritis and, 28–35
HLA-DR, induction of neovascularization of renal allograft rejection and, 347–353
HMG-COA reductase inhibitor, effect on high-sensitivity C-reactive protein and albumin in hemodialysis, 1213–1217
HMOs (health maintenance organizations), hemodialysis outcomes *vs.* fee-for-service plans, 796–804
Homocysteine
in end-stage renal disease and chronic renal failure, 134–145
in hemodialysis patients, methylenetetrahydrofolate reductase genotype and vitamin B_{12} effects on, 1032–1039
Host factors, in upper urinary tract infection caused by *E. coli*, 744–752
Hydronephrosis, after kidney transplantation, ultrasonography of, 663–678
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. *See* Simvastatin
Hypercalcemia, in renal transplant recipient with *pneumocystis carinii* pneumonia, 2:E8

Hypercalciuria, in congenital lactic acidosis, 12–23
Hypercholesterolemia, of chronic renal dialysis patients, simvastatin for, 283–290, 419–421
Hyperhomocysteinemia, vitamin B_{12} and MTHFR genotype effects in hemodialysis patients, 1032–1039
Hyperoxaluria, late-onset primary type 1, 2:E11
Hyperparathyroidism, secondary
  with parathyroid gene polymorphism in hemodialysis patients, 1255–1260
  treatment protocol for hemodialysis patients, 1270–1277
Hyperphosphatemia, sustained, renal osteodystrophy and, 1270–1277
Hypertension
  in ADPKD, relationship of renal volume growth and renal function in, 1127–1134
  of African American chronic renal failure patients, health-related quality of life and, 513–524
  in chronic kidney disease, S1:48
  development in primary low-grade immunoglobulin A nephropathy, 401–406
  effect of decreasing dry weight in PD by increasing ultrafiltration volume, 872–875
  glomerular filtration rate and, 112–119, S1:29
  glomerulosclerosis of, stereological features of, 678–688
  hemodialysis-associated, pathophysiology and therapy for, 227–244
  in hemodialysis patients, blood pressure measurement methods for, 1226–1230
  in high-altitude polycythemia, 1135–1142
  management, sensitivity/specificity of proteinuria dipstick test for, 1190–1195
  microalbuminuria prevalence and, 445–459
  pharmocotherapy, during hemodialysis, exercise effects on, 828–833
  in type 2 diabetic nephropathy, renal function decline with cigarette smoking, 376–382
Hyperuricemia, in high-altitude polycythemia, 1135–1142
Hypocomplementemic urticarial vasculitis, with monoclonal gammopathy and renal insufficiency, 203–207
Hypokalemic paralysis, aristolochic acid-induced Fanconi's syndrome, with nephropathy presenting as, 3:E14
Hypoparathyroidism, in hemodialysis, risk factors and mortality risk of, 1245–1254
Hypotension, interdialytic, effects of midodrine and cool dialysate, 102–107
Hypothyroidism, thyroxine requirement changes in renal transplant patients, 354–357

Icodextrin, efficacy and safety for automated peritoneal dialysis, 862–871
Imaging studies, as chronic kidney disease marker, S1:104–105
Immunoadsorption, for systemic lupus erythematosus with tuberculosis, 415–418
Immunoglobulin A nephropathy
  antiendomysial antibodies in, 1176–1182
  CD44 expression in, 407–414
  prevalence in Zuni Indians, 358–368
  primary low-grade, progression of, 401–406
  proximal tubule osteopontin mRNA expression, 948–957
  regression after methylprednisolone and tonsillectomy, 493–502
  uteroglobulin gene polymorphism and, 36–41
Immunoglobulin G deposition, in membranoproliferative glomerulonephritis, 706–712
Immunohistochemistry, of E-cadherin/catenin complex in glomerulonephritis, 469–474
Immunoproliferative lesions, angiocentric pulmonary, with diffuse renal involvement, 3:E12
Immunosuppression
  development of urinary tract infection caused by *E. coli* and, 744–752
  with immunoabsorption for systemic lupus erythematosus with tuberculosis, 415–418
  prognosis, histologic characteristics at time of diagnosis and, 28–35
Immunotherapy, failure, in metastatic renal cell carcinoma, capecitamine for, 48–54
Infantile cystinosis
  presenting as chronic constipation, 6:E24
  presenting as constipation, 6:E24
Infection rates, impact of NKF-DOQI on, 549–555
Inflammation, protein-energy malnutrition in chronic renal failure and, 422–425
Insulin-like growth factor-1, in posttransplantation erythrocytosis, angiotensin II receptor antagonist and ACE inhibitor effects on, 600–608
Integrins, in hemodialysis-induced neutropenia, 587–593
Interdialytic Hypotension, effects of midodrine and cool dialysate, 102–107
Interferon-α, for cryoglobulinemic glomerulonephritis, 876–888
Interleukin-6
  prediction of carotid artery atherosclerosis in dialysis patients, 274–282
  release, effect on serum albumin and CRP with different hemodialysis membranes, 266–273
Intermittent hemodialysis, citrate anticoagulation with calcium-containing dialysate for, 315–323
Intermittent mechanical ventilation, renal function effects, 616–624
Interstitial nephritis
  celecoxib-induced, 1313–1317
  with monoclonal gammopathy and urticarial vasculitis, 203–207
Intestinal iron absorption, indirect evaluation of, 594–599
Intima media thickness, in chronic renal failure, 1206–1212
Intradialytic hemodynamics, cool dialysate, midodrine and, 102–107
Intravascular coil, for renal transcatheter arterial embolization of ADPKD, 571–579
Intravascular large B-cell lymphoma, case study, 892–895
Iron
  deficiency, in chronic kidney disease, 426–432
  intestinal absorption, indirect evaluation of, 594–599
  status, measurement of, 426–432
Iron therapy
  for anemia of chronic kidney disease, 426–432
  for hemodialysis patients, evaluation of intestinal iron absorption in, 594–599

Ischemic heart disease
as cause of death in ESRD, 146–153
with persistent elevated CRP in CAPD patients, 342–346

Japanese patients, with adult-onset minimal change nephrotic syndrome, steroid responsiveness of, 503–512
Jeune's syndrome, type 2, retransplantation in, 2:E9

Kidney biopsy. *See* Renal biopsy
Kidney Disease Quality of Life-Short Form (KDQOL-SF), effect of early dialysis initiation of HRQOL, 108–115
Kidney function
after aortic stent-grafting crossing renal artery ostia, 730–736
loss, in chronic kidney disease, factors associated with, 170–197, S1:30–31
modeling reciprocal of creatinine *vs.* time in renal transplant recipients and chronic renal failure, 753–761
Kidney-lung syndrome, spontaneous and protracted partial remission in, 1113–1117
Kidney-pancreas transplantation, cytomegalovirus infection impact on, 1088–1095
Kidney transplantation
allograft rejection, induction of neovascularization in, 347–353
chronic allograft nephropathy risk, pretransplant C-reactive protein and, 1096–1101
complications, varicella virus infection, 1310–1312
cytomegalovirus infection impact on, 1088–1095
donors, cadaveric, universal conscription for, 609–615
for ESRD in fee-for-service plans *vs.* HMOs, 796–804
for hypothyroid patients, thyroxine requirement changes in, 354–357
malignancy after, 1:E5
ultrasonography in, 663–678
Kinetic modeling, for hemodialysis patients, reproducibility of bipedal bioelectrical impedance analysis, 154–158
Kt/V, postdialysis calculation, stop dialysate flow method for, 308–314

Laboratory evaluation, of kidney disease, S1:26–27. *See also specific biochemical parameters*
Lactic acidosis, congenital, renal manifestations of, 12–23
Laser microdissection, proximal tubule biopsy sections, OPN mRNA quantification in, 948–957
Least squares method, for modeling reciprocal of creatinine *vs.* time in renal transplant recipients, 753–761
Left ventricular hypertrophy, reduction, ACE inhibitors for, 227–244
Leptin, renal disease and, 1–9
Leukemia, with tubulointerstitial nephritis and meningocephalitis, BK virus regulatory region rearrangements in, 1102–1112
Leukocytes
adhesion, in hemodialysis-induced neutropenia, 587–593
hemodialysis-activated, at interstitial inflammation site, 854–861
Ligation of accessory veins, for salvaging nonmaturing arteriovenous fistulae, 824–827
Light chains, in crystal-storing histiocytosis with low-grade B-cell lymphoproliferative disorder, 183–188
Lipid abnormalities, in chronic renal failure, fluvastatin for, 67–75
Lipid-lowering therapy, for hypercholesterolemic chronic renal dialysis patients, 283–290
Lipid peroxidation, mitochrondrial respiratory chain function in chronic renal failure and, 1025–1031
Lipoproteins
in chronic renal failure, fluvastatin effect on, 67–75
in ESRD, vitamin E-bonded hemodialyzer and, 127–133
Losartan
effects on hemoglobin, circulating erythropoietin and IF-1, 600–608
reduction of urinary TGF-β1, 486–492
with/without captopril, effect on angiotensin II plasma and kidney tissue levels, 159–164
Low-density lipoprotein (LDL)
elevated in chronic renal dialysis patients, diet *vs.* simvastatin for, 283–290, 419–421
oxidized, increase with vitamin E-bonded hemodialyzer, 127–133
subclass B, modulation of endothelial cells, 972–984
Lupus membranoproliferative glomerulonephritis, mimicking hepatitis-C associated nephropathy, 3:E19
Lupus nephritis
with ANCA-negative renal vasculitis in child, 433–438
E-cadherin/catenin complex expression in, 469–474
with tuberculosis, steroids with immunoabsorption for, 415–418
Lymphoceles, after kidney transplantation, ultrasonography of, 663–678
Lymphocytes, in neovascularization induction in renal allograft rejection, 347–353
Lymphoma
intravascular large B-cell, 892–895
primary cerebral with membranous nephropathy, 6:E22

Macroangiopathy, ACE serum activity in type 2 diabetes mellitus and, 1054–1060
Macrophages, in neovascularization induction in renal allograft rejection, 347–353
Malignant hypertension, with cardiac tamponade, 3:E17
Malondialdehyde, decrease with vitamin E-bonded hemodialyzer, 127–133
Marginal zone lymphoma, crystal-storing histiocytosis in, 183–188
Maternal age, congenital renal agenesis and, 689–693
Mechanical ventilation, renal function effects, 616–624
Medical Outcomes Study 36-Item Short-Form Health Survey, effect of early dialysis initiation of HRQOL, 108–115
Medicare, hemodialysis outcomes *vs.* HMOs, 796–804
Membranoproliferative glomerulonephritis (MGN)
bucillamine-induced, 706–712
glomerulosclerosis of, stereological features of, 678–688
lupus, mimicking hepatitis-C associated nephropathy, 3:E19
oral interferon-α for, 876–888
Membranous nephropathy
glomerular plasminogen activator inhibitor type I in, 695–705
with primary cerebral lymphoma, 6:E22

Meningocephalitis, with leukemia and tubulointerstitial nephritis, BK virus regulatory region rearrangements in, 1102–1112
Mesangial cell injury, renal structure changes in diabetes mellitus and, 985–1000
Mesangial proliferative glomerulonephritis, vascular growth factor and proteinuria in, glucocorticoid effects on, 1001–1010
Metabolic acidosis, protein-energy malnutrition in chronic renal failure and, 422–425
Methemoglobinemia, hemodialysis-associated in acute renal failure, 1307–1309
Methylenetetrahydrofolate reductase genotype, effect on plasma homocysteine levels in hemodialysis patients, 1032–1039
Methylprednisolone, with tonsillectomy, IgA nephropathy regression after, 493–502
Mexican Americans, antioxidant vitamins-serum creatinine relationship and, 460–468
MGN. *See* Membranoproliferative glomerulonephritis
Mice, with cryoglobulinemic glomerulonephritis, oral interferon-α therapy for, 876–888
Microalbuminuria
  screening, albumin-creatinine ratio for, 1183–1189
  spot albumin-creatinine ratio prediction of, 1183–1189
  in U.S. population, 445–459
β_2-Microglobulin, urinary excretion in normotensive pregnancy and preeclampsia, 392–400
Microscopic polyangiitis, spontaneous and protracted partial remission in, 1113–1117
Midodrine, intradialytic hemodynamics and, 102–107
Minimal-change nephrotic syndrome
  glomerular tip lesion in, 1168–1175
  proximal tubule osteopontin mRNA expression, 948–957
  steroid-resistant, prediction of outcome with pulse methylprednisolone therapy, 1143–1152
  steroid responsiveness and frequency of relapse in, 503–512
Mitochondrial myopathies, renal manifestations of, 12–23
Mitochrondrial respiratory chain function, in chronic renal failure, 1025–1031
Monoclonal gammopathy, with urticarial vasculitis and renal insufficiency, 203–207
Mononuclear cell infiltration, and tubulointerstitial injury in angiogenesis induction, 347–353
Mortality
  cardiovascular risk in dialysis patients, QTc dispersion for identification of, 834–842
  of ESRD in HMOs *vs.* fee-for-service plans, 796–804
  HCFA and HEMO Study comparison of causes of death, 146–153
  hospital-acquired renal insufficiency, 930–936
  of long-term hemodialysis survivors, 533–538
  risk of hypoparathyroidism in hemodialysis, 1245–1254
  in uremic patients with acute myocardial infarction, 539–548
Multiple myeloma, pamidronate therapy, nephrotic syndrome after, 1118–1122
Mupirocin resistance, after long-term usage, in chronic peritoneal dialysis patients, 337–341
Myeloperoxidase-antineutrophil cytoplasmic antibody-associated glomerulonephritis, with diabetic nephrosclerosis, 1:E4

N-Acetyl-β-Dglucosaminidase (NAG), urinary excretion in normotensive pregnancy and preeclampsia, 392–400
National Center for Health Statistics, pulmonary embolism risk in chronic dialysis, 1011–1017
National Institutes of Health, Hemodialysis Study. *See* HEMO Study
National Institutes of Health-funded hemodialysis study. *See* HEMO Study
National Kidney Foundation DOQI. *See* Dialysis Outcomes Quality Initiative
Native Americans, end-stage renal disease prevalence in, 358–368
Needle gauge, arterial pressure in chronic dialysis and, 1231–1235
Neovascularization, induction in renal allograft rejection, macrophages and lymphyocytes in, 347–353
Nephrolithiasis prevention, pediatric potassium citrate dosage for, 383–391
Nephrotic syndrome
  after pamidronate treatment, 1118–1122
  childhood, T-lymphocyte populations and cytokines in, 958–965
  rare cause of, 892–895
  steroid-resistant, prediction of outcome with pulse methylprednisolone therapy, 1143–1152
Neuropathy, glomerular filtration rate and, S1:156–160
Neutropenia, hemodialysis-induced, CD11/CD18 adhesion molecule in, 587–593
Neutrophil function, in ESRD, vitamin E-bonded hemodialyzers and, 127–133
NHANES III. *See* Third National Health and Nutrition Examination Survey
Nitric oxide synthase, placental, pregnancy outcome in CsA-treated transplant recipients and, 776–783
NKF-DOQI. *See* Dialysis Outcomes Quality Initiative
Nuclear factor-κ B transcriptional activity, activation by low-density lipoprotein subclass B, 972–984
Nuclear magnetic resonance spectroscopy, of 5-fluorouracil pharmacokinetics in chronic hemodialysis, 2:E10
Nutrition
  body weight deficits in continuous ambulatory peritoneal dialysis and, 1068–1077
  constipation prevalence in CAPD *vs.* hemodialysis patients, 1292–1299
  fish intake, dialysis survival and, 1018–1024
  glomerular filtration rate and, 128–142, S1:29
  of HEMO Study cohort at baseline, 245–256
  lipid-lowering, for hypercholesterolemia of chronic renal dialysis patients, 283–290

Obesity, leptin and, 1–9
Osteoblasts, in diabetic hemodialysis patients, bone turnover disease and, 1261–1269
Osteocalcin
  in diabetic dialysis patients, 1261–1269
  in hemodialysis patients, 291–296
Osteoclastogenesis inhibitor factor. *See* Osteoprotegerin

Osteodystrophy
analysis in dialysis patients, 1270–1277
in diabetic in hemodialysis patients, mechanisms of, 1261–1269
osteoprotegerin as marker for, in hemodialysis patients, 580–586
Osteopenia, diabetic in hemodialyzed patients, impaired PTH secretion in mechanism of low bone turnover, 1261–1269
Osteopontin mRNA expression, in minimal change nephrotic syndrome and IgA nephropathy, 948–957
Osteoporosis detection, in dialysis-dependent renal failure patients, 843–849
Osteoprotegerin
circulating levels in chronic renal failure, 525–532
as marker for high-turnover osteodystrophy and decreased mineralization in hemodialysis patients, 580–586
Oxidative stress, in ESRD, vitamin E-bonded hemodialyzers and, 127–133

Pamidronate, nephrotic syndrome after, 1118–1122
papG class II allele, development of urinary tract infection caused by *E. coli* and, 744–752
Paraquat poisoning, failure of CVVH to prevent death in, 55–59
Parathyroid hormone (PTH)
in hemodialysis patients, 291–296
impaired secretion in diabetic hemodialyzed patients, low bone turnover and, 1261–1269
as osteodystrophy marker for hemodialysis patients, 580–586
skeletal resistance in chronic renal failure, osteoprotegerin and, 525–532
Parathyroid hormone gene polymorphism, and secondary hyperparathyroidism in hemodialysis patients, 1255–1260
Parenchymal injury
after kidney transplantation, ultrasonography of, 663–678
as determinant of clinical consequences in atherosclerotic renal artery stenosis, 1321–1322
renal function outcome in arteriosclerotic renovascular disease and, 1153–1161
Patient satisfaction, with care and behavioral compliance in hemodialysis for ESRD, 1236–1244
Pax2 transcription factor, cellular lesion development in focal segmental glomerulosclerosis and, 475–485
Peak oxygen uptake, exercise capacity in ESRD and, 76–85
Percutaneous transluminal renal angioplasty, outcome prediction for renal artery stenosis, 60–66
Perinatal factors, in congenital renal agenesis, 689–693
Peripheral vascular resistance, intradialytic effects of midodrine *vs.* cool dialysate, 102–107
Peritoneal dialysis (PD)
adequacy
in Chinese patients, 1287–1291
DOQI guidelines, S1:60–61
automated, icodextrin solution for, 862–871
chronic
infection patterns in, 1278–1286
mupirocin resistance after long-term use for *Staphylococcus aureus* colonization, 337–341
for chronic renal failure, arterial wall properties and, 1206–1212
end-stage renal disease prognostic factors, 1196–1205
exit-site infection prevention, antimicrobial-impregnated catheters for, 165–173
NKF-DOQI guidelines, impact of, 784–795
plasminogen activator inhibitor-1 4G/5G polymorphism and, 1061–1067
repeat peritonitis, development of new strategies for, 1318–1320
serum albumin, reduction in extracellular fluid volume and, 872–875
Peritoneal dialysis catheters, antimicrobial-impregnated, for exit-site infection prevention, 165–173
Peritoneal dialysis solution, icodextrin, efficacy and safety for automated peritoneal dialysis, 862–871
Peritoneal transport
in Chinese PD therapy patients, 1287–1291
plasminogen activator inhibitor-1 4G/5G polymorphism and, 1061–1067
Peritonitis
multiple episodes in chronic PD therapy patients, 1278–1286
prevention, antimicrobial-impregnated CAPD catheters for, 165–173
repeat, in PD therapy patients, development of new strategies for, 1318–1320
Pharmacoeconomics, exercise during hemodialysis, decreases antihypertensive drug usage, 828–833
Phenotypic change, early in focal segmental glomerulosclerosis podocytes, 475–485
Pheochromocytoma
in anephric von Hippel-Lindau disease, diagnosis during laparoscopic adrenalectomy, 2:E6
multisystem crisis in endocrine neoplasia type IIB and pyelonephritis, 6:E23
Phosphaturia, in congenital lactic acidosis, 12–23
Phosphorus, in hemodialysis patients, 291–296
Phosphorus metabolic disorders, glomerular filtration rate and, S1:143–155
Placenta vasoactive factor imbalance, pregnancy outcome in CsA-treated transplant recipients and, 776–783
Plasmapheresis, long-term prognosis of rapidly progressive glomerulonephritis and, 28–35
Plasminogen activator inhibitor-1
4G/5G genetic polymorphism, peritoneal transport characteristics and, 1061–1067
glomerular expression in glomerulonephritis, 695–705
Pneumocystis carinii pneumonia, with hypercalcemia in renal transplant recipient, 2:E8
Pneumonia
Pneumocystis carinii, with hypercalcemia in renal transplant recipient, 2:E8
Rhodococcus equi, medical management in renal transplant recipient, 2:E7
Podocytes
early phenotypic change in focal segmental glomerulosclerosis, 475–485
structural alterations, in focal segmental glomerulosclerosis, 625–636

Polyarteritis, spontaneous and protracted partial remission in, 1113–1117
Polycystic kidney disease, with citrullinemia, long-term hemodialysis for, 189–192
Polycythemia, high-altitude, hyperuricemia, hypertension and proteinuria in, 1135–1142
Polymyxin B-immobilized fiber, in direct hemoperfusion for endotoxin removal, 937–947
Population-based survey
  cross-sectional, of Zuni Indians, 358–368
  of microalbuminuria, 445–459
Positive end-expiratory pressure, effect on renal function, 616–624
Postdialysis urea rebound, stop dialysate flow method and, 308–314
Postembolism syndrome, reduction after renal angiomyolipoma ablation, 966–971
Posttransplantation erythrocytosis, angiotensin II receptor antagonist and ACE inhibitor effects on, 600–608
Potassium citrate dosage, for pediatric nephrolithiasis prevention, 383–391
Potassium intake, constipation prevalence in CAPD *vs.* hemodialysis patients, 1292–1299
Prednisolone, reduction of postembolism syndrome after renal angiomyolipoma ablation, 966–971
Preeclampsia, urinary biochemical parameters in, 392–400
Pregnancy
  normotensive, urinary biochemical parameters in, 392–400
  outcome in CsA treated transplant recipients, placental vasoactive factors and, 776–783
Prenatal factors, in congenital renal agenesis, 689–693
Privacy issues, genetic disorders and, 637–652
Progression
  of chronic renal failure, slowing, 721–729
  despite AT1 receptor blockade, transforming growth factor-β1 production and, 486–492
  determinants, in focal segmental glomerulosclerosis, 625–636
  of glomerulosclerosis, glomerular size and, 678–688
  of low-grade primary immunoglobulin A nephropathy, 401–406
  risk stratification, 170–212, S1:30–31
Protein
  catabolic rate, of HEMO Study cohort at baseline, 245–256
  IgA nephropathy and, 36–41
  intake, of HEMO Study cohort at baseline, 245–256
  normal excretion, S1:50
  urinary excretion, renal function decline in type 2 diabetic nephropathy and, 376–382
  urinary total, in normotensive pregnancy and preeclampsia, 392–400
Protein-energy malnutrition, causes in chronic renal failure, 422–425
Protein receptors, in albumin uptake from glomerular ultrafiltrate, 899–919
Proteinuria
  in adults, S1:52–53
  assessment guidelines, S1:93–102
  in children, S1:53
  in congenital lactic acidosis, 12–23
  definition of, S1:50
  development in primary low-grade immunoglobulin A nephropathy, 401–406
  dipstick test performance characteristics, 1190–1195
  in high-altitude polycythemia, 1135–1142
  as kidney damage marker, S1:49–50
  lack of, in GK rats after induction of anti-thy1 nephritis, 985–1000
  in mesangial proliferative glomerulonephritis, glucocorticoid effects on, 1001–1010
  OPN mRNA expression in proximal tubules, 948–957
  prevalence in U.S., 445–459
  progression despite ACE inhibition, TGF-β1 production and, 486–492
  renal volume growth in ADPKD and, 1127–1134
Proteoglycans, renal structure changes in diabetes mellitus and, 985–1000
Proximal tubules
  abnormalities, in congenital lactic acidosis, 12–23
  osteopontin mRNA expression in minimal change nephrotic syndrome and IgA glomerulonephropathy, 948–957
PTH. *See* Parathyroid hormone
Pulmonary embolism risk, in chronic dialysis patients, 1011–1017
Pulmonary renal syndrome, single-center four-year experience, 42–47
Pulse methylprednisolone therapy, outcome prediction for steroid-resistant nephrotic syndrome, 1143–1152
Pyleonephritis, in endocrine neoplasia type IIB with pheochromocytoma multisystem crisis, 6:E23
Pyridoxic acid, in end-stage renal disease and chronic renal failure, 134–145
Pyridoxin, in end-stage renal disease and chronic renal failure, 134–145
Pyruvate dehydrogenase abnormalities, renal manifestations of, 12–23

QTc dispersion
  in identifying increased risk of cardiovascular mortality in dialysis patients, 834–842
  in uremic patients with acute myocardial infarction, 539–548
Quality of life
  assessment after kidney-pancreas transplantation, 1300–1306
  health-related, early initiation of dialysis and, 108–115
  for hemodialysis caregivers, 805–812

Race
  congenital renal agenesis and, 689–693
  microalbuminuria prevalence and, 445–459
Radiographic contrast media, hospital-acquired renal insufficiency and, 930–936
Rats
  angiotensin II levels, effect of ACE inhibitor plus angiotensin II receptor blocker on, 159–164
  antimicrobial-impregnated PD catheters for exit-site infection prevention, 165–173

Goto-Kakizaki, protection from proteinuria after induction of anti-thy1 nephritis, 985–1000
with mesangial proliferative glomerulonephritis, glucocorticoid effects on, 1001–1010
Recombinant human erythropoietin (rHuEPO)
for hemodialysis patients, evaluation of intestinal iron absorption in, 594–599
predialysis *vs.* postdialysis hemocrits during, 850–853
Reimbursement, for dialysis, quality of care and, 116–126
Relapse frequency, of minimal-change nephrotic syndrome, 503–512
Renal agenesis, case-control analysis of birth characteristics, 689–693
Renal artery ostia, stent-graft crossing effects on, 730–736
Renal artery stenosis
after kidney transplantation, ultrasonography of, 663–678
parenchymal injury as determinant of clinical consequences in, 1321–1322
PTRA outcome prediction for, 60–66
Renal biopsy
acute interstitial nephritis, unusual presentation of, 653–658
different renal damage patterns in diabetes mellitus, 713–720
of glomerular tip lesion in minimal change nephropathy, 1168–1175
proximal tubule sections, OPN mRNA quantification in, 948–957
repeat, of immunoglobulin A nephropathy regression, 493–502
Renal cell carcinoma, capecitabine therapy after immunotherapy failure, 48–54
Renal contraction therapy, for ADPKD by transcatheter arterial embolization, 571–579
Renal masses, in acute interstitial nephritis, 653–658
Renal osteodystrophy. *See* Osteodystrophy
Renal replacement therapy. *See* Hemodialysis; Kidney transplantation; Peritoneal dialysis
Renal transcatheter arterial embolization, for autosomal dominant polycystic kidney disease, 571–579
Renal transplant recipients
chronic allograft nephropathy risk, pretransplant C-reactive protein and, 1096–1101
CsA-treated, placental vasoactive factor imbalance and pregnancy outcome, 776–783
medical management of *Rhodococcus equi* pneumonia in, 2:E7
modeling reciprocal of creatinine *vs.* time in, 753–761
with *pneumocystis carinii* pneumonia, hypercalcemia in, 2:E8
with pretransplant Alport's syndrome, 769–775
Renal tubular acidosis, pediatric, potassium citrate dosage for urinary abnormality correction, 383–391
Renal tubule assist device, for metabolic renal substitution therapy in uremia, 1078–1087
Renal vein thrombosis, after kidney transplantation, ultrasonography of, 663–678
Renal volume growth, renal function in ADPKD and, 1127–1134
Renin-angiotensin-aldosterone system, in hemodialysis-associated hypertension, 227–244
Resistance index, preoperative, of native arteriovenous fistulae, 1218–1225
Respiratory chain abnormalities, renal manifestations of, 12–23
Retransplantation, in type 2 Jeune's syndrome, 2:E9
Review of articles, methods for, S1:223–231
Rheumatoid arthritis, treatment, membranoproliferative glomerulonephritis development and, 706–712
Rhodococcus equi pneumonia, medical management in renal transplant recipient, 2:E7
rHuEPO. *See* Recombinant human erythropoietin

Schnitzler's syndrome, case study, 203–207
Schönlein-Henoch purpura, Goodpasture syndrome during, 5:E21
Sepsis, pulmonary renal syndrome mortality and, 42–47
Septic shock, endotoxin removal by direct hemoperfusion with polymyxin B-immobilized fiber, 937–947
Silver sulfadiazine, peritoneal dialysis catheter impregnation, effects of, 165–173
Simvastatin
effects on high-sensitivity CRP and albumin in hemodialysis, 1213–1217
for hypercholesterolemic chronic renal dialysis patients, 283–290, 419–421
Skeletal muscle, mitochondrial function preservation in young CRF patients, 1025–1031
Social support, for ESRD patients on chronic hemodialysis, 1236–1244
Sodium restriction, for hemodialysis-associated hypertension, 227–244
Solitary kidney, congenital renal agenesis, 689–693
Staphylococcus aureus
in chronic PD therapy patients, 1278–1286
colonization in chronic peritoneal dialysis patients, mupirocin resistance in, 337–341
Staphylococcus epidermidis infections, in chronic PD therapy patients, 1278–1286
Stent grafting, crossing renal artery ostia, effects on renal function, 730–736
Steroid therapy
reduction of postembolism syndrome after renal angiomyolipoma ablation, 966–971
responsiveness, of minimal-change nephrotic syndrome, 503–512
with tonsillectomy, IgA nephropathy regression after, 493–502
Stop dialysate flow method, for predicting 30-minute postdialysis blood urea, 308–314
Sudden death, QTc dispersion for identification at dialysis initiation, 834–842
Superimposed glomerulopathies, in diabetes mellitus, 713–720
Surveillance, impact of NKF-DOQI on, 549–555
Survival, dialysis, dietary fish intake and, 1018–1024
Sustained low-efficiency dialysis, for critical illness, urea kinetics during, 556–570
Systemic lupus erythematosus
with ANCA-negative renal vasculitis in child, 433–438
with tuberculosis, immunoabsorption for, 415–418

Tacrolimus, for cyclosporine-associated nephrotoxicity in heart transplant recipients, 3:E16
Third National Health and Nutrition Examination Survey (NHANES III)
methods/findings from, S1:232–235
microalbuminuria prevalence in U.S., 445–459
Thrombosis, of hemodialysis catheter, alteplase for, 86–91
Thrombotic microangiopathy, in African-American girl with systemic lupus erythematosus, 433–438
Thymic stromal lymphopoietin transgenic mice, oral interferon-α therapy for, 876–888
Thyroxine, requirement changes in renal transplant patients, 354–357
Tissue factor, pregnancy outcome in CsA-treated transplant recipients and, 776–783
Tissue plasminogen activator, glomerular, in glomerulonephritis, 695–705
T-lymphocyte populations, in childhood nephrotic syndrome, 958–965
Tonsillectomy, IgA nephropathy regression after, 493–502
Tonsil ulcerations, with ARF and Fanconi's syndrome after colloidal bismuth subcitrate intoxication, 3:E18
Total body water, bioelectrical impedance analysis reproducibility, 154–158
Transcatheter arterial embolization, for renal contraction in ADPKD, 571–579
Transferrin, in chronic kidney disease, 426–432
Transforming growth factor-β1
leptin and, 1–9
urinary, effect of AT1 receptor blockade with ACE inhibitors on, 486–492
Triclosan, peritoneal dialysis catheter impregnation, effects of, 165–173
Triglycerides, in hypercholesterolemic chronic renal dialysis patients, lipid-lowering therapy for, 283–290
Trisodium citrate, for anticoagulation with calcium-containing dialysate, 315–323
Tuberculosis, with systemic lupus erythematosus, steroids and immunoabsorption for, 415–418
Tuberous sclerosis complex, renal angiomyolipomas, reduction of postembolism syndrome after ablation, 966–971
Tubulointerstitial compartment, CD44 expression in immunoglobulin A nephropathy, 407–414
Tubulointerstitial injury, and mononuclear cell infiltration in angiogenesis induction, 347–353
Tubulointerstitial nephritis, with leukemia and meningocephalitis, BK virus regulatory region rearrangements in, 1102–1112
Tumor necrosis factor-α
activation by low-density lipoprotein subclass B, 972–984
in childhood nephrotic syndrome, 958–965
Tunnel infection, prevention, antimicrobial-impregnated CAPD catheters for, 165–173

Ultrafiltration
with icodextrin solution for automated peritoneal dialysis, 862–871
increased volume, effect on extracellular fluid volume and serum albumin, 872–875
Ultrasonography
calcaneal, inability to identify dialysis-dependent renal failure patients with fractures, 843–849
dilution, intradialytic hemodynamics and, 102–107
intravascular, for assessment of hemodialysis access, 813–823
in kidney transplantation, 663–678
preoperative, of native arteriovenous fistulae, 1218–1225
of renal volume growth, renal function in ADPKD and, 1127–1134
Uncoupling proteins, protein-energy malnutrition in chronic renal failure and, 422–425
United States population
antioxidant vitamin-serum creatinine relationship in, 460–468
microalbuminuria prevalence in, 445–459
United States Renal Data System (USRDS)
evaluation of NKF-DOQI guidelines, 784–795
long-term hemodialysis survivors, mortality rates/characteristics of, 533–538
pulmonary embolism risk in chronic dialysis, 1011–1017
Urea
blood, postdialysis, predicting using stop dialysate flow method-, 308–314
percentage of reduction in level, effect of needle gauge in chronic hemodialysis, 1231–1235
Urea clearance
body weight deficits in continuous ambulatory peritoneal dialysis and, 1068–1077
exercise capacity in ESRD and, 76–85
Urea nitrogen urinary excretion, in normotensive pregnancy and preeclampsia, 392–400
Urea reduction ratio, postdialysis prediction using stop dialysate flow method, 308–314
Urea space, bioelectrical impedance analysis, reproducibility in hemodialysis patients, 154–158
Uremia, with acute myocardial infarction, increased QTc dispersion and mortality in, 539–548
Uric acid
in high-altitude polycythemia, 1135–1142
urinary excretion, in normotensive pregnancy and preeclampsia, 392–400
Urinalysis, for hypertension management, sensitivity/specificity of proteinuria dipstick test for, 1190–1195
Urinary tract
congenital renal agenesis, 689–693
obstruction
after kidney transplantation, ultrasonography of, 663–678
development of urinary tract infection caused by *E. coli* and, 744–752
Urinary tract infection, caused by *E. coli*, host and bacterial factors in, 744–752
Urine sample
green, in critically ill patient, 4:E20
24-hour
electrophoretic pattern, *vs.* random sampling, 1:E2
for glomerular filtration rate estimation, S1:236–237
Urine sediment abnormalities, in chronic kidney disease, S1:103–104
USRDS. *See* United States Renal Data System

Uteroglobulin gene polymorphism, IgA nephropathy and, 36–41

Varicella vaccine, pretransplant immunization causing post-transplant infection, 1310–1312
Varicella virus infection, post-transplant, 1310–1312
Vascular access
  assessment, intravascular ultrasound for, 813–823
  flow rates, in upper-arm *vs.* lower-arm fistulas, 92–101
  impact of NKF-DOQI guidelines on, 784–795
  infection, impact of NKF-DOQI on, 549–555
  long-term survival of upper-arm fistula, 92–101
  nonmaturing arteriovenous fistulae, salvaging by percutaneous ligation of accessory veins, 824–827
  poorly developed, salvage with percutaneous ligation of accessory veins, 824–827
  sites, survival comparisons of, 92–101
  survival comparisons of lower-arm *vs.* upper-arm fistula, 92–101
  ultrasonographic assessment of, 813–823
Vascular disorders, after kidney transplantation, ultrasonography of, 663–678
Vascular endothelial growth factor, in mesangial proliferative glomerulonephritis, glucocorticoid effects on, 1001–1010
Vasculature, preoperative duplex sonography of native arteriovenous fistulae, 1218–1225
Vasculitis
  ANCA-negative with systemic lupus erythematosus, 433–438
  hypocomplementemic urticarial, with monoclonal gammopathy and renal insufficiency, 203–207
  long-term prognosis, effects of initial history and plasmapheresis on, 28–35
  pediatric periglomerular granulomatous reaction and, 1323–1327
  spontaneous and protracted partial remission in, 1113–1117
Vasodilatation, in hemodialysis-associated hypertension, 227–244
Ventricular arrhythmia, QTc dispersion in predicting sudden death, 834–842
Virulence factors, in upper urinary tract infection caused by *E. coli*, 744–752
Vitamin A, serum creatinine and, 460–468
Vitamin B_6, metabolism, in end-stage renal disease and chronic renal failure, 134–145
Vitamin B_{12}, effect on plasma homocysteine levels in hemodialysis patients, 1032–1039
Vitamin C (ascorbic acid), serum creatinine and, 460–468
Vitamin E, serum creatinine and, 460–468
Vitamin E-bonded hemodialyzers, in ESRD, neutrophil function and oxidative stress and, 127–133
Von Hippel-Lindau disease, anephric, diagnosis of pheochromocytoma during laparoscopic adrenalectomy, 2:E6

Wegener's glomerulonephritis, long-term prognosis, effects of initial history and plasmapheresis on, 28–35
WT1 transcription factor, cellular lesion development in FSGS, 475–485

Zuni Indians, end-stage renal disease prevalence in, 358–368